A new market report by Market Research Intellect on the Hemophilia Gene Therapy Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies. Hence, this research study serves as an important depository of the information for every market landscape. The report is segmented on the basis of types, end-users, applications, and regional markets.

The research study includes the latest updates about the COVID-19 impact on the Hemophilia Gene Therapy sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=274190&utm_source=COD&utm_medium=888

The report also emphasizes the initiatives undertaken by the companies operating in the market including product innovation, product launches, and technological development to help their organization offer more effective products in the market. It also studies notable business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions.

Leading Hemophilia Gene Therapy manufacturers/companies operating at both regional and global levels:

Sales and sales broken down by Product:

Sales and sales divided by Applications:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

The report also focuses on the global industry trends, development patterns of industries, governing factors, growth rate, and competitive analysis of the market, growth opportunities, challenges, investment strategies, and forecasts till 2026. The Hemophilia Gene Therapy Market was estimated at USD XX Million/Billion in 2016 and is estimated to reach USD XX Million/Billion by 2026, expanding at a rate of XX% over the forecast period. To calculate the market size, the report provides a thorough analysis of the market by accumulating, studying, and synthesizing primary and secondary data from multiple sources.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=274190&utm_source=COD&utm_medium=888

The market is predicted to witness significant growth over the forecast period, owing to the growing consumer awareness about the benefits of Hemophilia Gene Therapy. The increase in disposable income across the key geographies has also impacted the market positively. Moreover, factors like urbanization, high population growth, and a growing middle-class population with higher disposable income are also forecasted to drive market growth.

According to the research report, one of the key challenges that might hinder the market growth is the presence of counter fit products. The market is witnessing the entry of a surging number of alternative products that use inferior ingredients.

Key factors influencing market growth:

Reasons for purchasing this Report from Market Research Intellect

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=274190&utm_source=COD&utm_medium=888

Customization of the Report:

Market Research Intellect also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

To summarize, the Hemophilia Gene Therapy market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

More here:
Hemophilia Gene Therapy Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Opportunities and Forecast 2026 - Cole of Duty

Recommendation and review posted by Bethany Smith

A new market report by Market Research Intellect on the Gene Therapy Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies. Hence, this research study serves as an important depository of the information for every market landscape. The report is segmented on the basis of types, end-users, applications, and regional markets.

The research study includes the latest updates about the COVID-19 impact on the Gene Therapy sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=304727&utm_source=COD&utm_medium=888

The report also emphasizes the initiatives undertaken by the companies operating in the market including product innovation, product launches, and technological development to help their organization offer more effective products in the market. It also studies notable business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions.

Leading Gene Therapy manufacturers/companies operating at both regional and global levels:

Sales and sales broken down by Product:

Sales and sales divided by Applications:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

The report also focuses on the global industry trends, development patterns of industries, governing factors, growth rate, and competitive analysis of the market, growth opportunities, challenges, investment strategies, and forecasts till 2026. The Gene Therapy Market was estimated at USD XX Million/Billion in 2016 and is estimated to reach USD XX Million/Billion by 2026, expanding at a rate of XX% over the forecast period. To calculate the market size, the report provides a thorough analysis of the market by accumulating, studying, and synthesizing primary and secondary data from multiple sources.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=304727&utm_source=COD&utm_medium=888

The market is predicted to witness significant growth over the forecast period, owing to the growing consumer awareness about the benefits of Gene Therapy. The increase in disposable income across the key geographies has also impacted the market positively. Moreover, factors like urbanization, high population growth, and a growing middle-class population with higher disposable income are also forecasted to drive market growth.

According to the research report, one of the key challenges that might hinder the market growth is the presence of counter fit products. The market is witnessing the entry of a surging number of alternative products that use inferior ingredients.

Key factors influencing market growth:

Reasons for purchasing this Report from Market Research Intellect

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=304727&utm_source=COD&utm_medium=888

Customization of the Report:

Market Research Intellect also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

To summarize, the Gene Therapy market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

See original here:
Gene Therapy Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Opportunities and Forecast 2026 - Cole of Duty

Recommendation and review posted by Bethany Smith

With last weeks retractions of two Covid-19 papers from a pair of the worlds top medical journals, the scientific community is once again wrestling withthe question that arises any time ahigh-profile publication blows up: Could this have been prevented?

Entire forests have been felled so scholars can write papers on the flawed process of peer review, in which journal editors ask (usually three) outside experts to read a manuscript for rigor, methodological soundness, consistency, and overall quality. Peer review is rife with gender bias. Reviewers try to block competitors papers. They steal ideas. They favor authors from prestigious institutions. The process is hardly better than chance at keeping bad studies from being published. It does little to improve papers.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

Follow this link:
After retractions of two Covid-19 papers, scientists ask what went wrong - STAT

Recommendation and review posted by Bethany Smith

Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market: Strategic Analysis of Industry Trends, Technologies, Participants, and Environment by Kelly Scientific is a comprehensive report and financial forecast to 2025 on the precision medicine industry and its impact on the health system. This report tackles the growing market interest in pharmacogenomics, targeted therapeutics, companion diagnostics and the associated market environment.

Get Free Sample Copy of Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2025 Research Report at https://www.reportsnreports.com/contacts/requestsample.aspx?name=3330473

In 2019, 11 personalized therapeutics gained approval from the the FDAs Center for Drug Evaluation and Research (CDER) including a gene therapy and a small interfering ribonucleic acid (siRNA) based therapy. Over 20% of all new approvals in 2019 were personalized therapeutics and in 2018 alone, 42% were personalized medicines (25 agents). This was an increase from 34% in 2017 and 27% in 2016. Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics will be more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine will reduce the frequency of adverse drug reactions and therefore have a dramatic impact on health economics. Developmental and diagnostic companies will benefit from lower discovery and commercialization costs and more specific market subtypes.

This report describes the current technologies that are propelling the Personalized Medicine and Companion Diagnostic Market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in key markets such as the US, UK, Germany and France are elucidated and analysed. This study reveals market figures of the overall personalized medicine market and also sub-market figures.

The study also provides a comprehensive financial and product review of key players in the personalized medicine industry. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.

In summary, the personalized therapeutic and associated companion diagnostic market have huge opportunities for growth. This industry is revolutionizing the healthcare system and will improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics. This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by over 360 tables & figures over 470 pages. The personalized medicine market is presented as follows:

A wealth of financial data & business strategy information is provided including:

Get 20% Discount on this Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=3330473

SWOT, Economic & Regulatory Environment specifics include:

This report highlights a number of significant players and influential companys and gives details of their operations, products, financials and business strategy.

Updates on the Personalized medicine, targeted therapeutic and companion diagnostic space have been included in this latest edition to include cutting edge material from international conferences, workshops and symposia.

Direct Purchase of Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2025 Research Report at https://www.reportsnreports.com/purchase.aspx?name=3330473

Countries Covered

Global, US, UK, France, Germany, Spain, Italy, Europe

Table of Contents:

1.0 Executive Summary

2.0 Introduction to Precision/Personalized Medicine

3.0 Personalized Medicine Targeted Therapeutics and Associated Companion Diagnostics

4.0 Personalized Medicine and Integration into the Healthcare System

5.0 Private and Public Funding and Personalized Medicine Reimbursement

6.0 European Personalized Medicine Market Payments and Investment

7.0 Personalized Medicine Business Model Analysis

8.0 Personalized Medicine Main Industry Players

9.0 Personalized Medicine Market Analysis

10.0 Strengths and Advantages of Personalized Medicine

11.0 Restraints of the Personalized Medicine Market

12.0 Personalized Medicine and Regulatory Policies

13.0 Final Summary and Future Perspectives

14.0 Interviews with Key Opinion Leaders

Read the rest here:
Personalized Medicine Market, Targeted Therapeutics and Companion Diagnostic Market to 2025 Key Company Profiles, Trends and Technologies Report - 3rd...

Recommendation and review posted by Bethany Smith

Global Neurologic Disorders Therapeutics Market: Overview

In todays age, neurologic disorders are becoming increasingly common, especially neurodegenerative diseases. According to various studies, the growth of these neurological disorders is spreading rapidly across Europe and other parts of the world. In addition to this, the treatment for such disorders is also very challenging because of the presence of the strictly regulated blood-brain barrier. It is also challenging due to the unique ability to cover the brain from the new therapeutics. Traditional therapeutics, although effective, are still below the optimum level required for efficient treatment. Hence, there is need for finding newer and more effective therapeutics. This has thus given rise to the neurologic disorders therapeutics market.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6000

Global Neurologic Disorders Therapeutics Market: Notable Developments

Some of the notable developments in the global neurologic disorders therapeutics market are listed below:

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6000

Names of other notable players in the global neurologic disorders therapeuticsmarket are listed below:

Global Neurologic Disorders Therapeutics Market: Drivers and Restraints

There are several factors that are influencing the growth of the global neurologic disorders therapeutics market. One of the key driving factors is the increasing advances in the diagnosis of the different neurodegenerative indications. This has helped in increasing the demand for new therapeutics to effectively treat such neurodegenerative disorders. The early determination such disorders is difficult due to its complex nature of such disorders, lack of efficient diagnostics, and its fast progression. This has naturally helped in driving the activities of research and development for more effective treatment. Governments across the globe are also helping research institutes by allotting more funds for the development of new neurologic disorder therapeutics.

Global Neurologic Disorders Therapeutics Market: Geographical Outlook

The global neurologic disorders therapeutics market is primarily divided into five key regions viz. North America, Latin America, the Middle East and Africa, Europe, and Asia Pacific. Of these, the global neurologic disorders therapeutics market is primarily dominated by North America region. This is because of the high aging population in the region, advancements in technology, and highly developed healthcare infrastructure.

Get Discount on Latest Report @https://www.tmrresearch.com/sample/sample?flag=D&rep_id=6000

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

See original here:
Neurologic Disorders Therapeutics Market Analysis Global Trends and Dynamic Demand by Forecast 2018 to 2028 - 3rd Watch News

Recommendation and review posted by Bethany Smith

A New York family was recently witness to overwhelming kindness from friends and strangers alike, in a quest to save their children.

Jennie and Gary Landsman are parents to Benny and Josh, two young boys ages 4 and 3. The boys suffer from Canavan disease, a rare, life-threatening progressive brain disorder. Most children with Canavan disease die by age ten. Three years ago the Landsmans were told by doctors that there is nothing they can do to save their boys.

But despite the grim prognosis, the Landsmans did not give up hope on finding a solution.

Through doing research on Canavan, they learnt about Dr. Paola Leone, a renowned neuroscientist, and director of the Cell and Gene Therapy Center at Rowan Universitys School of Osteopathic Medicine in New Jersey. As one of the top experts on Canavan disease in the world, Leone and her team have been working on developing cutting edge treatments for neurological diseases for over 20 years.

Through working with Dr. Leone it became apparent that finding a cure would mean much more than saving their children. If the therapy works as expected, scientists will then use the research and apply the gene therapy treatment to other brain disorders such as Alzheimers, Parkinsons, ALS, and Multiple Sclerosis. This means the Landsmans had a chance to help a much larger part of the population.

Although the hope was great, the price tag seemed insurmountable. The Landsmans needed $650,000 right after Shavuos, to pay for the last invoice to the drug manufacturer to release the treatment.

After coming so far, the Landsmans were not ready to give up. They started a Chesed Fund campaign in the hopes that at least a portion of the money would be raised.

Much to their surprise, not only was their goal met, it in fact was exceeded! Over the past two weeks over 7,000 new donors stepped up and donated generously. Over $550K has been raised and another $100K has been pledged. The final payment for the medication was made, and Benny and Josh will finally have their much needed treatment!

At this point, there is just one final chapter remaining. Each child will require approximately 3 weeks in the hospital. These hospital stays are not covered by insurance companies. These three weeks consist of a one week stay prior to the operation to deliver the gene therapy, during which they will undergo monitoring, testing, and MRIs. Approximately two weeks after the surgery, the children will need to be monitored in the ICU, with follow ups over the subsequent weeks and months to monitor the effects. The estimated cost for all the hospital stays is $280K per child.

Once the last $560K is raised, the Landsmans will finally be able to close this chapter for good, and Benny and Josh will be able to enjoy a happy and healthy life just like other children around them.

To help the Landsmans achieve their goal of saving their children and making medical history by contributing towards a cure for Multiple Sclerosis, ALS or even Alzheimers disease, visit their Chesed Fund Page HERE.

Please daven for:

More:
Overcoming Impossible Odds, Frum Couple Continues The Fight To Save Their Children - Yeshiva World News

Recommendation and review posted by Bethany Smith

Gene Therapy Market [Forecast 2020-2029] Industry Research Report analyzed in detail with all the vital data to frame strategic business decisions and propose vital development plans. This Gene Therapy report offers a complete understanding into the development policies and plans in addition to manufacturing processes and cost structures.

The report is a brilliant presentation of critical dynamics, regional growth, rivalry, and other significant parts of the Gene Therapy Market. The factual, unbiased, and thorough assessment of the worldwide Gene Therapy market presented in the report assures players of access to much-required data and information to plan effective growth strategies. The report has made a brilliant attempt to provide a comprehensive research study on major key companies, industry value chain, deployment models, and key opportunities, drivers, and restraints of the global Gene Therapy market. It shows how the global Gene Therapy market will advance or lack growth during each year of the forecast period. Readers are offered with detailed and near-accurate predictions of CAGR and market size of the global Gene Therapy market and its important segments.

To Get Premium Sample Copy of This Report@Download FREE Sample PDF!!

(***Our FREE SAMPLE COPY of the report gives a brief introduction to the research report outlook, TOC, list of tables and figures, an outlook to key players of the market and comprising key regions.***)

Market Segmentation Outlook: Gene Therapy Market

The report offers deep insights into leading segments of the worldwide Gene Therapy market and explains key factors helping them to collect a larger share. It provides accurate growth rate and market size accomplished by each segment during the forecast period. This Gene Therapy industry will help players to identify lucrative segments and plan out specific strategies to gain maximum profit from them. The report also includes sales growth, revenue, and price changes observed in important segments. Most importantly, the segmental analysis equips players with helpful data and information to make the best of opportunities available in various fragments.

Gene Therapy Market Segmentation Based On Leading Contenders-

Novartis, Kite Pharma Inc, GlaxoSmithKline PLC, Spark Therapeutics Inc, Bluebird bio Inc, Genethon, Transgene SA, Applied Genetic Technologies Corporation, Oxford BioMedica PLC, NewLink Genetics Corp., Amgen Inc

Gene Therapy Market Segmentation Based On vector type, gene type, application, and region-

By Vector: Viral vector, Retroviruses, Lentiviruses, Adenoviruses, Adeno Associated Virus, Herpes Simplex Virus, Poxvirus, Vaccinia Virus, Non-viral vector, Naked/Plasmid Vectors, Gene Gun, Electroporation, Lipofection. By Gene Therapy: Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth factors, Receptors, Other. By Application: Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious disease, Other Diseases

Gene Therapy Market Segmentation Based On Regional Analysis-

Europe (Germany, Russia, UK, Italy, Turkey, France, etc.)

The Middle East and Africa (GCC Countries and Egypt)

North America (United States, Mexico, and Canada)

South America (Brazil etc.)

Asia-Pacific (China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

To know How COVID-19 Pandemic Will Impact This Market/Industry-Click Here To Request COVID-19 Impact Analysis!!!

(**NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.)

Essential Findings of the Gene Therapy Market Report:

Ongoing and pipeline R&D projects in the Gene Therapy market sphere

Marketing and promotional strategies adopted by major key companies in the Gene Therapy market

Current and future prospects of the Gene Therapy market in various regional markets

Y-o-Y growth of the different segments and sub-segments in the Gene Therapy market

The domestic and international presence of leading market players in the Gene Therapy market

The following are taken into consideration:

Historical Period: 20142019

Forecast Period: 2020 to 2029

What Businesses Can Hope to Get in Business Intelligence on Gene Therapy Market?

The study insights on the Gene Therapy market growth dynamics and opportunities highlights various key aspects, in which crucial ones are:

i. Which are the technology and strategic areas that emerging, new entrants, and established players should focus on keep growing in the industry-wide disruptions that COVID-19 has caused?

ii. Which new avenues bear incredible potential during the ongoing COVID-19 lockdown restrictions?

iii. Which policies by governments can give the top stakeholders support their efforts of consolidation?

iv. What new business models are gathering pace among companies to remain agile in post-COVID-era?

v. Which segments will see a surge in popularity in near future, and what calibrations players need to make to utilize the trend for an elongated period?

|| Inquire/Speak To Expert for Further Detailed Information About Gene Therapy Report:https://marketresearch.biz/report/gene-therapy-market/#inquiry

Insights and Perspectives that make this Study on Gene Therapy Market Stand Out

The analysts who have prepared the report have been keen observers of the dynamism due to macroeconomic upheavals. Using the best industry assessment quantitative methods and data integration technologies, they have come out with a holistic overview of the future growth trajectories of the Gene Therapy market. Fact-based insights and easy-to-comprehend information based on wide spectrum of market data is what makes this study different from competitors.

Why Choose Us:

We offer industry-leading critical reports with accurate insights into the future of the market.

Our reports have been evaluated by some industry experts in the market, thus making them beneficial for the companys to maximize their return on investments.

We provide a comprehensive pictorial representation of the information, strategic recommendations, outcomes of the analytical tools to offer an elaborate landscape, highlighting the key market players. This detailed assessment of the market will help the company increase efficiency.

The demand and supply dynamics offered in the report give a 360-degree view of the market.

Our report helps readers decipher the current and future constraints in the Gene Therapy Market, and help them formulate optimum business strategies to maximize growth in the market.

Table of Content:-

1 Introduction of Gene Therapy Market

1.1 Overview of the Market

1.2 Scope of Report

1.3 Assumptions

2 Executive Summary

3 Research Methodology of MarketResearch.biz

3.1 Data Mining

3.2 Validation

3.3 Primary Interviews

3.4 List of Data Sources

4 Gene Therapy Market Outlook

4.1 Overview

4.2 Market Dynamics

4.2.1 Drivers

4.2.2 Restraints

4.2.3 Opportunities

4.3 Porters Five Force Model

4.4 Value Chain Analysis

5 Gene Therapy Market , Segmentation

5.1 Overview

6 Gene Therapy Market , By Geography

6.1 Overview

6.2 North America

6.2.1 U.S.

6.2.2 Canada

6.2.3 Mexico

6.3 Europe

6.3.1 Germany

6.3.2 U.K.

6.3.3 France

6.3.4 Rest of Europe

6.4 Asia Pacific

6.4.1 China

6.4.2 Japan

6.4.3 India

6.4.4 Rest of Asia Pacific

6.5 Rest of the World

6.5.1 Latin America

6.5.2 Middle East

7 Gene Therapy Market Competitive Landscape

7.1 Overview

7.2 Company Market Ranking

7.3 Key Development Strategies

8 Company Profiles

8.1.1 Overview

8.1.2 Financial Performance

8.1.3 Product Outlook

8.1.4 Key Developments

9 Appendix

9.1 Related Research

Click Here To View Complete TOC of Gene Therapy Market Report at:https://marketresearch.biz/report/gene-therapy-market/#toc

Contact Us At

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

See the original post here:
Gene Therapy Market Business Growth Statistics and Key Players Insights[PDF] |Addressing the Potential Impact of CoronaVirus (COVID-19) - TechnoVally

Recommendation and review posted by Bethany Smith

By focusing on the market conditions and market trends, market research study is initiated depending on the clients requirements. The report presents you with the persistent knowledge and information of transforming the market landscape, what already exists in the market, future trends, the market expectations, the competitive environment, and strategies that can be planned to outperform the competitors. Along with a thorough competitive analysis, the Global Stem Cell Manufacturing Market report also provides company profiles and contact information of the key market players in the key manufacturers section. Even clear research studies are performed devotedly to offer you an excellent market research report for your niche.

Stem Cell Manufacturing Marketis expected to reach USD 16.51 Billion by 2025, from USD 10.28 Billion in 2017 growing at a CAGR of 6.1% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic years 2017, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Get Sample Report PDF | @http://databridgemarketresearch.com/request-a-sample/?dbmr=global-artificial-intelligence-market

The Global Stem Cell Manufacturing Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of stem cell manufacturing market for global, Europe, North America, Asia Pacific and South America.

Major Market competitors/players: Global Stem Cell Manufacturing Market

Some of the major players operating in the stem cell manufacturing market are Thermo Fisher Scientific. Merck Group, Becton, Dickinson and Company. Holostem Advanced Therapies, JCR Pharmaceuticals, Organogenesis Inc, Osiris Therapeutics, Osiris Therapeutics, Vericel Corporation, AbbVie, American CryoStem, AM-Pharma, Anterogen.Co.,Ltd, Astellas Pharma, Bristol-Myers Squibb, Apceth Biopharma, Cellular Dynamics International, Rheacell, Takeda Pharmaceutical, Teva Pharmaceutical Industries Ltd. ViaCyte, VistaGen Therapeutics Inc, Translational Biosciences, GlaxoSmithKline plc, Daiichi Sankyo Company, Limited, among others.

Global Stem Cell manufacturing Market,By Application (Research Applicationsand Clinical Applicationsand Cell and Tissue Banking), By Product (Stem Cell Line, Instruments, Culture Media and Consumables), By End Users (Hospitals and Surgical Centers, Pharmaceutical and Biotechnology Companies, Clinics, Community Healthcare, Others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2025

Table of Contents:

Highlights of the Study

Inquire about this report from our experts @https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-stem-cell-manufacturing-market

Major Market Drivers:

Report Scope

Our purpose is to serve you, the most customised in-depth Market access data. Our plethora of titles, made us one of the most searched market research library across the globe. We work with the most esteemed Publishers around the globe who caters vast industries. We are quick and fragile, when it comes to your various queries, and we ensure our team cater your needs to the best of our abilities, we promise to stay by your side for both pre and post sales servicing, as we believe in long everlasting symbiotic relationship.

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email:[emailprotected]

More here:
GLOBAL STEM CELL MANUFACTURING MARKET (Covid 19 UPDATE) Competitive Insights, Trends and Demand Growth 2020 to 2027 - 3rd Watch News

Recommendation and review posted by Bethany Smith

The Global Hemophilia B Market research report 2020 to 2027 thoroughly explains each and every aspect related to the Global Hemophilia B Market, which facilitates the reports reader to study and evaluate the upcoming market trend and execute the analytical data to promote the business. The growth trend forecasted on account of thorough examination offers in-depth information regarding the global Hemophilia B Market.

Get a Sample Copy of this Report: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hemophilia-b-market

The major players covered in the report are:

Baxter, Grifols S.A., CSL Limited, Octapharma, Novo Nordisk A/S, Kedrion S.p.A, Pfizer Inc., Bayer AG, Biogen, Takeda Pharmaceuticals Company Limited, F. Hoffmann-La Roche Ltd, Ferring B.V., Sanofi, Swedish Orphan Biovitrum AB, BioMarin.

Market Analysis and Insights of Global Hemophilia B Market

Global hemophilia B market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market.

The global hemophilia B market is majorly driven high prevalence of hemophilia B and huge financial investment in research and development activities. In addition, high diagnostic rate and emergence of gene therapy to improve the treatment are some of the impacting factors that drive the market growth. Nevertheless, limited revenue opportunities coupled with high treatment cost significantly hinder the growth of this market.

Haemophilia is an inherited, rare, genetic bleeding disorder in which patients blood has insufficient levels of a clotting protein called factor IX. It is caused by mutation in F9 gene on the X chromosome and is considered the second most common form of hemophilia.

The advancement in the digital work force managements and empowering healthcare IT infrastructure and its surging player penetration in the medical industry are helping the Hemophilia B market to grow exponentially during the anticipated time frame of 2020 to 2027. Some of the other factors driving the market growth are as follows, affirmative management assistance and leadership, expense beneficiary constituents of the healthcare alliance business, and yielding decreases in pharmaceutical error frequency and enhancements in care standards are helping the market to make progress.

Important Features that are under offering & key highlights of the report:

Detailed overview of Hemophilia B market

Changing market dynamics of the industry

In-depth market segmentation by Type, Application etc

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape of Hemophilia B market

Strategies of key players and product offerings

Potential and niche segments/regions exhibiting promising growth

A neutral perspective towards Hemophilia B market performance

Market players information to sustain and enhance their footprint

Why choose us:

We share precise and exact information about the market forecast;

Our reports have been examined by professional experts of the industry, which makes them beneficial for the company to maximize their return on investment;

The analysis acknowledges that the sector players key drivers of both conflicts and Hemophilia B growth assess the impact of limitations as well as the opportunities on the sector;

Data regarding Hemophilia B industry share by every item fragment, alongside their reasonable worth, have been served in the report;

We provide statistic information, strategic and analysis tool results to provide a sophisticated landscape and target key market players. This will help the company to increase its efficiency;

Our report helps readers decipher the current and future constraints of the Hemophilia B market and optimal business strategies to enhance market development;

Want Full Report? Enquire here @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-hemophilia-b-market

This report sample includes

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (presentation)

Research methodology adopted by Data Bridge Market Research

Table Of Contents

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Research Methodology

Part 04: Market Landscape

Part 05: Pipeline Analysis

Part 06: Market Sizing

Part 07: Five Forces Analysis

Part 08: Market Segmentation

Part 09: Customer Landscape

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers and Challenges

Part 13: Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

Part 16: Appendix

Find More Competitor in TOC with Profile Overview Share Growth Analysis @ https://www.databridgemarketresearch.com/toc/?dbmr=global-hemophilia-b-market

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe, MEA or Asia Pacific.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

See the original post here:
Massive Growth of Hemophilia B Market By 2027 |Strong Revenue and Competitive Outlook: Baxter, Grifols SA, CSL Limited, Octapharma, Novo Nordisk A/S,...

Recommendation and review posted by Bethany Smith

Viral Vector & Plasmid DNA ManufacturingMarket reports provides a comprehensive overview of the global market size and share.Viral Vector & Plasmid DNA Manufacturingmarket data reports also provide a 5 year pre-historic and forecast for the sector and include data on socio-economic data of global. Key stakeholders can consider statistics, tables & figures mentioned in this report for strategic planning which lead to success of the organization

Get Sample Copy of this Report https://www.orianresearch.com/request-sample/1588058

What You Can Expect From Our Report:

Purchase Directly@ https://www.orianresearch.com/checkout/1588058

The report firstly introduced the Viral Vector & Plasmid DNA Manufacturing basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis. The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the Viral Vector & Plasmid DNA Manufacturing market.

Key CompaniesMerckuniQureThe Cell and Gene Therapy CatapultWaisman BiomanufacturingAddgeneCreative BiogeneNovasepCobra BiologicsAldevr

Key Product Type, Adenovirus, Retrovirus, Plasmid DNA, Others, Market by Application, Biopharmaceutical Companies, Research Institutes,

Global Viral Vector & Plasmid DNA Manufacturing Industry 2020 Market Research Report is spread across 63 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

What to Expect From This Report on Viral Vector & Plasmid DNA Manufacturing Market:

The developmental plans for your business based on the value of the cost of the production and value of the products, and more for the coming years.

A detailed overview of regional distributions of popular products in the Viral Vector & Plasmid DNA Manufacturing Market.

How do the major companies and mid-level manufacturers make a profit within the Viral Vector & Plasmid DNA Manufacturing Market?

Estimate the break-in for new players to enter the Viral Vector & Plasmid DNA Manufacturing Market.

Comprehensive research on the overall expansion within the Viral Vector & Plasmid DNA Manufacturing Market for deciding the product launch and asset developments.

Regions Covered in Viral Vector & Plasmid DNA Manufacturing Market are:-

North and South America

Europe

China

South Korea

Japan

India

Research Objectives of Viral Vector & Plasmid DNA Manufacturing Market:

To study and analyze the global Viral Vector & Plasmid DNA Manufacturing consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2020, and forecast to 2026.

To understand the structure of Viral Vector & Plasmid DNA Manufacturing market by identifying its various sub segments.Focuses on the key global Viral Vector & Plasmid DNA Manufacturing manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Viral Vector & Plasmid DNA Manufacturing with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the consumption of Viral Vector & Plasmid DNA Manufacturing submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

Major Points from Table of Contents1 Study Coverage1.1 Viral Vector & Plasmid DNA Manufacturing Product Introduction1.2 Key Market Segments in This Study1.3 Key Manufacturers Covered1.4 Market by Type1.4.1 Global Viral Vector & Plasmid DNA Manufacturing Market Size Growth Rate by Type1.4.2 Specialty Gas Grade (Low Purity)1.4.3 Research Grade (High Purity)1.5 Market by Application1.5.1 Global Viral Vector & Plasmid DNA Manufacturing Market Size Growth Rate by Application1.5.2 Nuclear Application1.5.3 Non-Nuclear Application1.6 Study Objectives1.7 Years Considered

2 Executive Summary2.1 Global Viral Vector & Plasmid DNA Manufacturing Production2.1.1 Global Viral Vector & Plasmid DNA Manufacturing Revenue 2014-20262.1.2 Global Viral Vector & Plasmid DNA Manufacturing Production 2014-20262.1.3 Global Viral Vector & Plasmid DNA Manufacturing Capacity 2014-20262.1.4 Global Viral Vector & Plasmid DNA Manufacturing Marketing Pricing and Trends2.2 Viral Vector & Plasmid DNA Manufacturing Growth Rate (CAGR) 2020-20262.3 Analysis of Competitive Landscape2.3.1 Manufacturers Market Concentration Ratio (CR5 and HHI)2.3.2 Key Viral Vector & Plasmid DNA Manufacturing Manufacturers2.3.2.1 Viral Vector & Plasmid DNA Manufacturing Manufacturing Base Distribution, Headquarters2.3.2.2 Manufacturers Viral Vector & Plasmid DNA Manufacturing Product Offered2.3.2.3 Date of Manufacturers Enter into Viral Vector & Plasmid DNA Manufacturing Market2.4 Market Drivers, Trends and Issues

3 Market Size by Manufacturers3.1 Viral Vector & Plasmid DNA Manufacturing Production by Manufacturers3.1.1 Viral Vector & Plasmid DNA Manufacturing Production by Manufacturers3.1.2 Viral Vector & Plasmid DNA Manufacturing Production Market Share by Manufacturers3.1.3 Global Market Concentration Ratio (CR5 and HHI)3.2 Viral Vector & Plasmid DNA Manufacturing Revenue by Manufacturers3.2.1 Viral Vector & Plasmid DNA Manufacturing Revenue by Manufacturers (2014-2020)3.2.2 Viral Vector & Plasmid DNA Manufacturing Revenue Share by Manufacturers (2014-2020)3.2.3 Global Viral Vector & Plasmid DNA Manufacturing Market Concentration Ratio (CR10 and HHI)3.3 Viral Vector & Plasmid DNA Manufacturing Price by Manufacturers3.4 Mergers & Acquisitions, Expansion Plans

4 Viral Vector & Plasmid DNA Manufacturing Production by Regions

5 Viral Vector & Plasmid DNA Manufacturing Consumption by Regions

6 Market Size by Type

7 Market Size by Application

8 Manufacturers Profiles

9 Production Forecasts

10 Consumption Forecast

11 Upstream, Industry Chain and Downstream Customers Analysis

12 Opportunities & Challenges, Threat and Affecting Factors

13 Key Findings

14 Appendix

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Customization Service of the Report:

Orian Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

More:
Viral Vector & Plasmid DNA Manufacturing Market to grow with a High CAGR- COVID-19 Impact Analysis, Global Key Manufacturers, Trends, Size,...

Recommendation and review posted by Bethany Smith

The new market report on CRISPR and Cas Genes is a comprehensive study providing analysis on factors trend and drivers contributing to growth of the Biotechnology. The report is prepared with reference to historic data .Estimation of contribution of segment is expressed in terms of volume and revenue for the forecast period. Market analysis and future prospect is segmented in various sections. Each sections focus on distinct features of the products that are anticipated to shape the market over the forecast period.

Some of the common segments mentioned in the report include market overview, tends, drivers, opportunities, restraints, regional segment, end-use application, and competitive landscape. The global revenues in CRISPR and Cas Genes market are projected to scale at a CAGR of 21.2% between 2020 and 2026.

Many stakeholders are consistently adopting new methodologies to boost growth of the market. Few investors are investing on research and development of new products, on the other hand, various companies are innovating the existing products.

Request to View Sample of Research Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=4823

In the wake of lockdown across various regions due to outbreak of COVID-19 pandemic, vendors in CRISPR and Cas Genes are focusing to enhance their customer reach using e-commerce channels.

Some of the insights and market estimations that make this study unique in approach and effective in guiding stakeholders in understanding the growth dynamics. The study provides:

The regional segmentation of the CRISPR and Cas Genes market is done as follows:

On the basis of product types, the CRISPR and Cas Genes market report offers insight into major adoption trends for the following segments:

Key end-users covered in the study include:

To Know More Information about This Report, Ask The Analyst: https://www.factmr.com/connectus/sample?flag=AE&rep_id=4823

Companies profiled in the report are:

How can Fact.MR Make Difference?

Contact:

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai, United Arab Emirates

MARKET ACCESS DMCC Initiative

Email: sales@factmr.com

Web: https://www.factmr.com/

The rest is here:
Impact of COVID-19 on CRISPR and Cas Genes Market, Infers Fact.MR - The Cloud Tribune

Recommendation and review posted by Bethany Smith

Last year, a bioengineer assistant professor at Stanford University named Stanley Qui used a gene-editing tool called CRISPR, which flights influenza, to develop their own technique called Prophylactic Antiviral CRISPR in human cells. Also known as PAC-MAN, a team from Stanford University now works alongside Berkeley's Molecular Foundry to see if they can apply the same technique to fight against coronavirus.

As the first case of SARS-CoV-2, Qi and his team thought, 'Why don't we try using our PAC-MAN technology to fight it?' By late March, the Stanford scientists collaborated with Michael Connolly, an engineer of the Biological Nanostructures Facility at Berkeley Lab's Molecular Foundry, so they can develop a new system that can deliver PAC-MAN into patients' cells.

The first CRISPRsystem was discovered by Yoshizumi Ishino from Osaka University in 1987. Repeating clustered DNA was observed to have interruptions in what would typically be consecutively arranged.

By 2001, Ruud Jansen, searching for interrupted repeats, coined the term Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR). His observation of the prokaryote repeat cluster being accompanied by homologous genes resulted in cas genes.

PAC-MAN is made up of the enzyme Cas13, a virus killer, and a strand of guide RNA, which commands Cas13 to destroy specific nucleotide sequences in the coronavirus's genome. By re-arranging COVID-19's genetic code, PAC-MAN could neutralize it and stop it from replicating internal cells.

Qi explained that the primary challenge of translating PAC-MAN from a molecular tool into an anti-virus therapy is finding an effective way to deliver it into respiratory cells. As SARS-CoV-2 invades the lungs, infected air sacs become inflamed and filled with fluid, causing difficulty in breathing."But my lab doesn't work on delivery methods," he said, as the lab posted a tweet in hopes of finding the right collaboration.

By late March, they learned about Connolly's work on synthetic molecules, or lipitoids, and needed his expertise in cellular delivery techniques. Lipitoids are synthetic peptide mimics or peptoids. Connolly has worked with Ron Zuckermann, his mentor who discovered the peptoid, for 20 years to demonstrate 'lipitoids' effectiveness in the delivery of DNA and RNA to a wide variety of cell lines'

Read Also: HK Airport's Disinfection Booth Claims to Kill Coronavirus Using Nano Needle in 40 Seconds

In May 2018, scientists studying lipitoids for potential therapeutic applications resulted that it is not harmful to the body and can deliver nucleotides by encapsulating them in nanoparticles the same size as a virus. Qi now hopes to add his CRISPR-based COVID-19 therapy to the Molecular Foundry's growing body of lipitoid delivery systems.

In late April, they tested a type of lipitoid, Lipitoid 1, which self-assembles with DNA and RNA into PAC-MAN carriers in a human epithelial lung cell sample. The initial trial went well as the SARS-CoV-2-targeting PAC-MAN reduced the synthetic solution by more than 90%. 'Berkeley Lab's Molecular Foundry has provided us with a molecular treasure that transformed our research,' Qi said.

Scientists from New York University and Karolinska Institute in Stockholm, Sweden will be joining the collaboration as they plan to test the PAC-MAN/lipitoid system in a live animal model infected with the virus. If successful, they may proceed to preclinical tests.

Conolly explained that 'an effective lipitoid delivery, coupled with CRISPR targeting, could enable a very powerful strategy for fighting viral disease not only against COVID-19 but possibly against newly viral strains with pandemic potential.' 'Everyone has been working around the clock trying to come up with new solutions," added Qi. 'It's very rewarding to combine expertise and test new ideas across institutions in these difficult times.'

Read Also:Meet Xenobots: World's First Living and Self-Healing Robots Using Stem Cells From Frog Embryos

See the rest here:
PAC-MAN vs COVID-19 - Scientists Are Developing Gene-Targeting Technology to Beat the Virus - Science Times

Recommendation and review posted by Bethany Smith

Imagine a world in which we can produce meat without animals, cure previously incurable diseases by editing an individuals genetic fabric, and manufacture industrial chemicals in yeast factories. The foundational technologies that could make all this possible largely exist. Rapid and ever-cheaper DNA sequencing has deepened our understanding of how biology works and tools such as CRISPR are now being used to recode biology to treat diseases or make crops less vulnerable to climate change. This is what we call the Bio Revolution.

Explored in a new McKinsey Global Institute research report, which we helped co-author, the Bio Revolution is already benefiting society. A confluence of breakthroughs in biological science and ever faster and more sophisticated computing, data analytics, and artificial intelligence technologies has powered scientific responses to the Covid-19 pandemic. Scientists sequenced the virus genome in weeks rather than months, as was the case in previous outbreaks. Bio innovations are enabling the rapid introduction of clinical trials of vaccines, the search for effective therapies, and a deep investigation of the transmission patterns of the virus.

The report estimates that bio innovations could alleviate between 1% and 3% of the total global burden of disease in the next 10 to 20 years from these applications roughly the equivalent of eliminating the global disease burden of lung cancer, breast cancer, and prostate cancer combined. Over time, if the full potential is captured, 45% of the global disease burden could be addressed using science that is conceivable today.

advertisement

As much as 60% of the physical inputs to the global economy today are either biological (such as wood for construction or animals bred for food) or nonbiological (such as cement or plastics) but could, in principle, be produced over time using biology. Nylon can already be made using genetically engineered yeast instead of petrochemicals, for instance, leather is being made from mushroom roots, and bacteria have made a type of cement.

This Bio Revolution has the potential to be as transformative to business and economies as the Digital Revolution that proceeded it, creating value in every sector, disrupting value chains, and creating new business opportunities. Businesses clearly see the potential investment in a new generation of biological technologies had already surged to more than $20 billion by 2018.

advertisement

Many applications are being commercialized. We identified a visible initial pipeline of about 400 use cases, almost all scientifically feasible today, that could create a direct economic impact of $2 trillion to $4 trillion in the next 10 to 20 years more than half of which is outside health, in sectors as diverse as agriculture and textile manufacturing.

The confluence of biology and computing is already creating new capabilities. Computing is accelerating discovery and throughput in biology. An explosion of biological data due to cheaper sequencing is being used by biotech companies and research institutes that are increasingly using robotic automation and sensors in labs. Biotech company Zymergen, for example, has found that throughput in biological screening can be increased up to 10 times. Advanced analytics, more powerful computational techniques, and AI are also being deployed to generate more acute insights during the R&D process.

New biology-based manufacturing is already cutting costs, improving performance, and reducing the impact on the environment and the natural world. In cosmetics, for instance, Amyris is now making squalane, a moisturizing oil used in many skin-care products, by fermenting sugars using genetically engineered yeast instead of processing liver oil from deep-sea sharks, which was not only expensive but threatened the species with extinction. In textiles, U.S. startup Tandem Repeat is producing self-repairing, biodegradable, and recyclable fabric using proteins encoded by squid genes.

The Bio Revolution could utterly change the food business as plant-based proteins and lab-grown meat gain popularity and in the process cut greenhouse gas emissions from deforestation and animal husbandry. One study found that cultured meat could reduce greenhouse gas emissions by 80% or more compared with conventional meat if all of the energy used in manufacturing comes from carbon-free sources.

Cultured meat and seafood are made using tissue-culture technology, a lab process by which animal cells are grown in vitro. Producers still face a major technical challenge in finding a cost-effective way of growing cells. New players such as Finless Foods, Mosa Meat, Memphis Meats, and Meatable are experimenting with different approaches, including using synthetic molecules and pluripotent stem cells to replace expensive growth factors. Cultured meat and seafood could be cost-competitive with conventional animal production systems within 10 years.

In agriculture, greater understanding of the role of the microbiome offers opportunities to improve operational efficiency and output. By profiling bacteria and fungi in the soil, Trace Genomics, for one, produces insights that help choose tailored seeds and nutrients, and enables early prediction of soil diseases. In consumer markets, ongoing research into the relationship between the gut microbiome and the skin is being used to personalize skin care. Singapore-based genomics firm Imagene Lab, for instance, offers a personalized serum based on the results of its skin DNA tests that assess traits such as premature collagen breakdown.

Such examples give a sense of the breadth of applicability of bio innovation, but there is a significant caveat: risk. Biology will preserve life through innovative treatments tailored to our genomes and microbiomes, but biology could also be the greatest threat to life if it is used to create bioweapons or genetically engineered viruses that can do lasting damage to the health of humans or ecosystems. The CRISPR gene-editing tool is revolutionizing medicine and is being applied to agriculture with great effect. But consider that CRISPR kits are now available to buy on the Internet for $100 and so-called biohackers are using them at home.

Like the Digital Revolution, the Bio Revolution comes with risks but of a different order of magnitude. If citizens already have misgivings about data being gathered about their shopping habits, how much more nervous will they be about genetic data gathered from their bodies for medical treatment or ancestry tracing data that couldnt be more personal.

Another risk is that biological organisms are, by their nature, self-sustaining and self-replicating. Genetically engineered microbes, plants, and animals may be able to reproduce and sustain themselves over the long term, potentially affecting entire ecosystems. Once Pandoras box is opened and we have already cracked the lid we may have little control over what happens next.

Unless such risks are managed, it is possible that the full potential of the Bio Revolution may not materialize. We estimate that about 70% of the total potential impact could hinge on societal attitudes and the way innovation is governed under existing regulatory regimes. Yet if the risks can be managed and mitigated, the Bio Revolution can reshape our world. Scientists, in conjunction with forward-thinking companies, are now harnessing the power of nature to solve pressing problems in medicine, agriculture, and beyond, and helping craft a response to global challenges from pandemics to climate change.

Matthias Evers is a senior partner and global leader of research and development in McKinsey & Companys pharmaceuticals and medical products practice. Michael Chui is a partner at the McKinsey Global Institute, McKinseys business and economics research arm.

Read the original post:
The Bio Revolution is changing business and society - STAT - STAT

Recommendation and review posted by Bethany Smith

A new market report by Market Research Intellect on the CRISPR And CRISPR-Associated (Cas) Genes Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies. Hence, this research study serves as an important depository of the information for every market landscape. The report is segmented on the basis of types, end-users, applications, and regional markets.

The research study includes the latest updates about the COVID-19 impact on the CRISPR And CRISPR-Associated (Cas) Genes sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=207429&utm_source=COD&utm_medium=888

The report also emphasizes the initiatives undertaken by the companies operating in the market including product innovation, product launches, and technological development to help their organization offer more effective products in the market. It also studies notable business events, including corporate deals, mergers and acquisitions, joint ventures, partnerships, product launches, and brand promotions.

Leading CRISPR And CRISPR-Associated (Cas) Genes manufacturers/companies operating at both regional and global levels:

Sales and sales broken down by Product:

Sales and sales divided by Applications:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

The report also focuses on the global industry trends, development patterns of industries, governing factors, growth rate, and competitive analysis of the market, growth opportunities, challenges, investment strategies, and forecasts till 2026. The CRISPR And CRISPR-Associated (Cas) Genes Market was estimated at USD XX Million/Billion in 2016 and is estimated to reach USD XX Million/Billion by 2026, expanding at a rate of XX% over the forecast period. To calculate the market size, the report provides a thorough analysis of the market by accumulating, studying, and synthesizing primary and secondary data from multiple sources.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=207429&utm_source=COD&utm_medium=888

The market is predicted to witness significant growth over the forecast period, owing to the growing consumer awareness about the benefits of CRISPR And CRISPR-Associated (Cas) Genes. The increase in disposable income across the key geographies has also impacted the market positively. Moreover, factors like urbanization, high population growth, and a growing middle-class population with higher disposable income are also forecasted to drive market growth.

According to the research report, one of the key challenges that might hinder the market growth is the presence of counter fit products. The market is witnessing the entry of a surging number of alternative products that use inferior ingredients.

Key factors influencing market growth:

Reasons for purchasing this Report from Market Research Intellect

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=207429&utm_source=COD&utm_medium=888

Customization of the Report:

Market Research Intellect also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

To summarize, the CRISPR And CRISPR-Associated (Cas) Genes market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Read the original:
CRISPR And CRISPR-Associated (Cas) Genes Market 2019 Break Down by Top Companies, Countries, Applications, Challenges, Opportunities and Forecast 2026...

Recommendation and review posted by Bethany Smith

The world was gaslit by misreporting about George Floyds initial autopsy report. As concerned physicians, we write to deconstruct the misinformation and condemn the ways this weaponization of medical language reinforced white supremacy at the torment of Black Americans.

Gaslighting is a method of psychological manipulation employed to make a victim question their own sanity, particularly in scenarios where they are mistreated. The term comes from a 1938 play and, later, a popular film, wherein a predatory husband abuses his wife in a plot to have her committed to a mental institution. He dims the gas lights in their home; then, when she comments on the darkness, knowingly rejects her observation and uses it as evidence that shes gone insane. Its a torturous tactic employed to destroy a persons trust in their own perception of reality. Its a devastating distraction from oppression. Its insidious. And it happened recently when millions of people who had seen nine agonizing minutes of murder were told by an autopsy report that they hadnt.

In America, widespread anti-Black violence is often paired with structural gaslighting. Racism, after all, thrives when blame for its outcomes are misattributed. When Black families are refused loans in criminally discriminatory housing schemes, their credit is blamed. When youth of color are disproportionately stopped and frisked, they are told the process is random, and for their safety.

And when Black people are killed by police, their character and even their anatomy is turned into justification for their killers exoneration. Its a well-honed tactic. One analysis of the national database of state-level death certificate data found that fewer than half of law enforcementrelated deaths were reported. In addition to this undercounting, police actions were further minimized by the use of diagnostic codes that incorrectly labeled the cause of death as accidental or undetermined rather than police-related. For centuries, our systems have relied on this psychological torturea host of mental gymnasticsto deny the truth of what Black people have always known. The cause of death is racism.

On May 29, the country was told that the autopsy of George Floyd revealed no physical findings that support a diagnosis of traumatic asphyxiation, and that potential intoxicants and preexisting cardiovascular disease likely contributed to his death. This requires clarification. Importantly, these commonly quoted phrases did not come from a physician, but were taken from a charging document that utilized politicized interpretations of medical information. As doctors, we wish to highlight for the public that this framing of the circumstances surrounding Floyds death was at best, a misinterpretation, and at worst, a deliberate obfuscation.

A timeline of events illustrates how a series of omissions and commissions regarding Mr. Floyds initial autopsy results deceptively fractured the truth. On May 28, a statement released by the Hennepin County Medical Examiners office reported ongoing investigations and acknowledgement from the forensic pathologist that an autopsy must be interpreted in the context of the pertinent investigative information. As per standardized medical examination, Floyds underlying health conditions and toxicology screen were documented. These are ordinary findings that do not suggest causation of death, yet headlines and the May 29 charging document falsely overstated the role of Floyds coronary artery disease and hypertension, which increase the risk of stroke and heart attack over years, not minutes. Asphyxiasuffocationdoes not always demonstrate physical signs, as other physician groups have noted.

Without this important medical context, however, the public was left to reconcile manipulated medical language with the evidence they had personally witnessed. Ultimately,the initial report overstated and misrepresented the role of chronic medical conditions, inappropriately alluded to intoxicants, and failed to acknowledge the stark reality that but for the defendants knee on George Floyds neck, he would not be dead today.

By Monday, June 1, in the context of widespread political pressure,the public received two reports: the preliminary autopsy report commissioned by Floyds family by private doctors, andshortly thereaftera summary of the preliminary autopsy from the Hennepin County Medical Examiners Office. Both reports stated that the cause of Floyds death was homicide: death at the hands of another.

By inaccurately portraying the medical findings from the autopsy of George Floyd, the legal system and media emboldened white supremacy, all under the cloak of authoritative scientific rhetoric. They took standard components of a preliminary autopsy report to cast doubt, to sow uncertainty; to gaslight America into thinking we didnt see what we know we saw. In doing so, they perpetuated stereotypes about disease, risky behavior and intoxication in Black bodies to discredit a victim of murder. This state of affairs is not an outlierit is part of a patterned and tactical distortion of facts wherein autopsy reports are manipulated to bury police violence and uphold white supremacy. As Ida B. Wells said, Those who commit the murders write the reports. A similar conflict of interest between police departments and medical examiners offices continues today.

As physicians, we will not be complicit in the ongoing manipulation of medical expertise to erase government-sanctioned violence. Though we are relieved that two independent examinations invalidated the preliminary findings in the charging document and the headlines that deceitfully undermined Chauvins culpability in Floyds murder, our initial incense is not replaced by celebration.

For three days, Black Americans satand still sitwith the all-too-familiar pangs of being told that the truth is not true. Of fearing that the law would believe a physicians report over the reality they saw with their own eyes, and have lived with their own lives. It's a miscarriage of justice that deepens the cut; not only can Black people be killed with impunity; a physicians autopsy report can be twisted to replace the truth.

Medical science has long been used for the consolidation of power rather than for solidarity with the oppressed. We see how Black mothers are blamed for their own mortality in childbirth and how starkly high rates of COVID death in Black communities are preposterously misattributed to differences in hormone receptors or clotting factors; all the while letting racism off the hook.

We wish to remind fellow physicians that medical science has never been objective. It has never existed in a vacuum; there have and will always be social, political and legal ramifications of our work. Our assessments may be employed in criminal justice cases; our toxicology screens may have profound effects on the livelihood of patients; our diagnoses may perpetuate sexist and racist stereotypes. Our lack of ill intent cannot be our alibiwe must be accountable for not just our work but also how it is used, lest our medicine becomes the very weapon that harms. Medicine requires inclusion of the social context of disease in order to uphold its sacred oath of doing no harm. If we focus only on molecular pathways and neglect to articulate the role of structural inequitiesof racismin our country, our reports on the causes of death and injury in our patients will erase the roles of their oppressors.

We also write to remind our physician colleagues that the medical field is a place ripe for gaslighting. Bolstered by the perceived strength and legitimacy of a white coat and a stethoscope, our diagnoses and conclusionsabout physical or psychological abnormalities, about causes of illness and deathhave the power to eclipse reality, as weve seen in the case of George Floyd. Often, we stand by while other agents co-opt our frameworks, obscure our research and weaponize our language in the service of oppression.

The declarations, the truths, the realities of Black people in America are too often disregarded. Across the nation, Black people are suffocating under the weight of anti-Black hatred. They cannot breathe. And even as they gasp for air, structural gaslighting operates to deny the truths of the causes of their suffocation.

We write as physicians to denounce this psychological manipulation. We write to apologize for the discrimination our patients of color have received in the hospital under our watch, we write in gratitude for the tireless labor of Black activists, and we write to condemn how medicine has been weaponized in the service of white supremacy. We write to validate what Black people already knowhave always knownthat racism is a most pressing public health crisis. We pledge to fight this crisis as if our own breath depended on it.

Read this article:
George Floyd's Autopsy and the Structural Gaslighting of America - Scientific American

Recommendation and review posted by Bethany Smith

Save your business while saving lives, reads the website of Because Health, a Seattle tech startup selling two types of tests to employers willing to pay $350 a pop to learn whether their workers have been infected with COVID-19.

The Workplace Health plan includes not only nasal swab tests to detect infection, but also blood tests aimed at indicating whether workers have developed antibodies to the virus and, possibly, future protection.

Theres a tremendous consumer demand, said Dr. Lars Boman, the Boston-based medical director for the firm. Can they return to work? Can they return to life?

What the website does not make clear, however, is that public health officials have explicitly warned that antibody tests should not be used to make decisions about workplace staffing.

This is a personal choice of the business, of the consumer, Boman said.

Across America, untold numbers of employers, employees and ordinary citizens are turning to a slew of sometimes pricey new COVID-19 blood tests. Knowing whos already been infected could have important implications for understanding the spread of the disease, scientists say. But serious questions about the accuracy of some of the serology tests and the usefulness of the results they provide have prompted the federal Food and Drug Administration to try to rein in what several infectious disease experts described as the wild, wild West of antibody testing.

It does look as if companies sprang up overnight both importing these tests and distributing them, said Dr. Michael Busch, director of the nonprofit Vitalant Research Institute in San Francisco. Its outrageous that people were trying to make money off of this fear.

More than 200 tests have flooded the market in a matter of weeks, promising to detect antibodies, which are proteins that develop in the blood as part of the bodys immune response to an invading virus. These are different from the molecular tests, typically done with nasal swabs, used to diagnose infection.

As of June 1, only 15 antibody tests had received FDA emergency-use authorizations, which allow tests that havent been fully vetted to be used in a crisis. Even that standard has become a selling point for some large companies, such as LabCorp and Quest Diagnostics, which emphasize that they rely on tests that have received the FDA nod.

In late May, the FDA removed more than 30 serology tests from a list of commercially available kits, saying they should not be distributed for sale. Removal could result from a manufacturer not submitting an emergency-use authorization request within a reasonable period of time, or if the test shows significant problems that cannot be or have not been addressed in a timely manner, the agency said. The manner of enforcement remains unclear.

Last month, the CDC issued new guidelines warning that, given the low prevalence of the virus in the general population, even the most accurate tests could be wrong half of the time.

Serologic test results should not be used to make decisions about grouping persons residing in or being admitted to congregate settings, such as schools, dormitories, or correctional facilities, the guidelines state. Serologic test results should not be used to make decisions about returning persons to the workplace.

Such tests are most useful for understanding the epidemiology of the virus, not for making individual decisions, said Dr. Mary Hayden, director of the division of clinical microbiology at Rush Medical Laboratories in Chicago. Even the best tests cant yet answer the crucial question about whether antibodies confer immunity from future COVID-19 infections, Hayden said.

The best possible scenario is that people get infected and they have protective immunity for a long time, she said. That would be awesome. But we just dont have that right now.

But a plethora of tests being pitched to consumers explicitly promise results aimed at allowing a return to work, school and other social arenas.

The tests offered by Because Health are among hundreds churned out since March, ranging from those offered by commercial labs and academic research centers to small developers seeking a toehold in the lucrative market spurred by a global pandemic. Because Health is using two antibody tests in tandem, one of which received emergency-use authorization on May 29; the other is still pending.

Anders Boman, the son of the medical director and co-founder of Because Health, said that until the COVID-19 crisis occurred, the company, which launched in Seattle last year, was focused on a niche of integrative care and sexual health, including hormone treatments for men and women.

Consumers are not concerned about sexual health right now, Boman said, explaining the change in focus. Theyre concerned about how to get back to work, how to return to normal and are they safe?

The FDA normally follows a stringent approval process for tests to detect diseases, often a costly effort that can take months or years. That typically requires independent validation of the accuracy of the tests. But after being criticized for the fumbled rollout of diagnostic tests during the start of a global pandemic, the FDA swung hard in the other direction, waiving its usual requirements and letting firms rush self-validated tests into the market.

They sort of relaxed all regulatory oversight, Hayden said.

Several experts interviewed by Kaiser Health News said the FDA faced tremendous political pressure to make antibody tests available.

It was really a single pressure and that was the fact that the original inability to get a (diagnostic) test on the market in the U.S. as the outbreak escalated means they were trying to do basically everything they could to get these out, said Michael Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota.

The relaxed rules drew concern from Congress, where a subcommittee of the Committee on Oversight and Reform detailed the FDAs failure to police the test market. Groups such as the Association of Public Health Laboratories also raised questions. Scott Becker, the APHLs chief executive, said he spoke to top officials at the U.S. Department of Health and Human Services in early April.

We just let loose and we said, This is a really bad policy, Becker said. Were going to get flooded and were going to lose control of quality. Were not going to know what to do with the results.

Thats exactly what has happened, said Osterholm. The FDA needs to bring much more discipline to this area and they need to articulate it clearly, he said.

A key issue is the accuracy of the tests, which rely on measures known as sensitivity and specificity. A highly sensitive test will capture all true positive results. A highly specific test would identify all true negative results.

In April, researchers at the University of California-San Francisco, led by immunologist Dr. Alexander Marson, analyzed 14 COVID-19 serology tests on the market and found that all but one turned up false-positive results, indicating that someone had antibodies to the coronavirus when they actually did not. False-positive rates reached as high as 16% in the study, which has not yet been peer-reviewed.

Unreliable results worry Dr. Jeff Duchin, the public health officer for Seattle and King County, Washington, where the first surge of COVID-19 cases emerged in the U.S. A person who tests positive for antibodies that dont exist may mistakenly believe he or she is free to ignore guidance about preventing infection, potentially spreading the disease. Regardless of whether you test positive or negative, the workplace still needs to take steps, he said. They shouldnt think a testing program in any way relieves them of that responsibility.

FDA officials said theyre working now with the National Cancer Institute to independently validate serology tests on the market. Until that list is public, users must rely on the relatively few that have received the emergency-use authorizations to date. More than 190 others have asked for that authorization, pending FDA review.

But consumers may have little control, because they are most likely getting tests from their employers or doctors, with little understanding of why those products were chosen.

There isnt a national standard, there isnt a one-stop shop or a Consumer Reports for antibody tests, Becker said. I dont expect a member of the public is going to be able to figure this out.

Even savvy physicians can have trouble. US Acute Care Solutions, a physician-owned medical services group, was trying out a Chinese-made test supplied by Minneapolis-based Premier Biotech, with plans to test its staff of more than 3,500 doctors and employees, said the groups chief medical officer, Dr. Amer Aldeen. That test has been widely used, including in recent controversial serology surveys conducted by Stanford University and the University of Southern California.

When USACS used it, the Premier test failed to detect antibodies in several employees who had been ill and tested positive for the coronavirus on diagnostic tests, Aldeen said. The results could have been caused by faulty instructions rather than flaws in the test itself, he said. Still, the Premier test has not received FDA authorization and the results gave him pause.

It does no good to select a test that isnt FDA-approved, he said.

In a statement, Premier Biotech officials said they anticipate exceeding FDA standards, which call for tests that are at least 90% accurate in identifying positive antibodies in a sample and 95% accurate in identifying samples that contain no antibody.

Some might ask why the FDA didnt just identify several reliable antibody tests and require their use to avoid the chaos. An FDA official said making that type of choice would be outside the scope of the agencys responsibilities.

FDAs lane is to review these tests and make sure that they are safe and accurate for the American people, said spokesperson Emma Spaulding. It wouldnt be within our lane to say which test must be used.

Although health officials understand the desire for a test that could provide comfort amid the uncertainty of COVID-19, Duchin advised employers and consumers to wait a little longer.

There are costs to testing with unvalidated tests that might outweigh the benefits of satisfying your curiosity, he said.

Read the original:
Hype collides with science as FDA tries to rein in 'wild west' of COVID-19 blood tests - Lebanon Democrat

Recommendation and review posted by Bethany Smith

JoNel Aleccia, Kaiser Health News and Anna Maria Barry-Jester

Save your business while saving lives, reads the website of Because Health, a Seattle tech startup selling two types of tests to employers willing to pay $350 a pop to learn whether their workers have been infected with COVID-19.

The Workplace Health plan includes not only nasal swab tests to detect infection, but also blood tests aimed at indicating whether workers have developed antibodies to the virus and, possibly, future protection.

Theres a tremendous consumer demand, said Dr. Lars Boman, the Boston-based medical director for the firm. Can they return to work? Can they return to life?

What the website does not make clear, however, is that public health officials have explicitly warned that antibody tests should not be used to make decisions about workplace staffing.

This is a personal choice of the business, of the consumer, Boman said.

Across America, untold numbers of employers, employees and ordinary citizens are turning to a slew of sometimes pricey new COVID-19 blood tests. Knowing whos already been infected could have important implications for understanding the spread of the disease, scientists say. But serious questions about the accuracy of some of the serology tests and the usefulness of the results they provide have prompted the federal Food and Drug Administration to try to rein in what several infectious disease experts described as the wild, wild West of antibody testing.

It does look as if companies sprang up overnight both importing these tests and distributing them, said Dr. Michael Busch, director of the nonprofit Vitalant Research Institute in San Francisco. Its outrageous that people were trying to make money off of this fear.

More than 200 tests have flooded the market in a matter of weeks, promising to detect antibodies, which are proteins that develop in the blood as part of the bodys immune response to an invading virus. These are different from the molecular tests, typically done with nasal swabs, used to diagnose infection.

As of June 1, only 15 antibody tests had received FDA emergency-use authorizations, which allow tests that havent been fully vetted to be used in a crisis. Even that standard has become a selling point for some large companies, such as LabCorp and Quest Diagnostics, which emphasize that they rely on tests that have received the FDA nod.

In late May, the FDA removed more than 30 serology tests from a list of commercially available kits, saying they should not be distributed for sale. Removal could result from a manufacturer not submitting an emergency-use authorization request within a reasonable period of time, or if the test shows significant problems that cannot be or have not been addressed in a timely manner, the agency said. The manner of enforcement remains unclear.

Last month, the CDC issued new guidelines warning that, given the low prevalence of the virus in the general population, even the most accurate tests could be wrong half of the time.

Serologic test results should not be used to make decisions about grouping persons residing in or being admitted to congregate settings, such as schools, dormitories, or correctional facilities, the guidelines state. Serologic test results should not be used to make decisions about returning persons to the workplace.

Such tests are most useful for understanding the epidemiology of the virus, not for making individual decisions, said Dr. Mary Hayden, director of the division of clinical microbiology at Rush Medical Laboratories in Chicago. Even the best tests cant yet answer the crucial question about whether antibodies confer immunity from future COVID infections, Hayden said.

The best possible scenario is that people get infected and they have protective immunity for a long time, she said. That would be awesome. But we just dont have that right now.

But a plethora of tests being pitched to consumers explicitly promise results aimed at allowing a return to work, school and other social arenas.

The tests offered by Because Health are among hundreds churned out since March, ranging from those offered by commercial labs and academic research centers to small developers seeking a toehold in the lucrative market spurred by a global pandemic. Because Health is using two antibody tests in tandem, one of which received emergency-use authorization on May 29; the other is still pending.

Anders Boman, the son of the medical director and co-founder of Because Health, said that until the COVID crisis occurred, the company, which launched in Seattle last year, was focused on a niche of integrative care and sexual health, including hormone treatments for men and women.

Consumers are not concerned about sexual health right now, Boman said, explaining the change in focus. Theyre concerned about how to get back to work, how to return to normal and are they safe?

The FDA normally follows a stringent approval process for tests to detect diseases, often a costly effort that can take months or years. That typically requires independent validation of the accuracy of the tests. But after being criticized for the fumbled rollout of diagnostic tests during the start of a global pandemic, the FDA swung hard in the other direction, waiving its usual requirements and letting firms rush self-validated tests into the market.

They sort of relaxed all regulatory oversight, Hayden said.

Several experts interviewed by Kaiser Health News said the FDA faced tremendous political pressure to make antibody tests available.

It was really a single pressure and that was the fact that the original inability to get a [diagnostic] test on the market in the U.S. as the outbreak escalated means they were trying to do basically everything they could to get these out, said Michael Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota.

The relaxed rules drew concern from Congress, where a subcommittee of the Committee on Oversight and Reform detailed the FDAs failure to police the test market. Groups such as the Association of Public Health Laboratories also raised questions. Scott Becker, the APHLs chief executive, said he spoke to top officials at the U.S. Department of Health and Human Services in early April.

We just let loose and we said, This is a really bad policy, Becker said. Were going to get flooded and were going to lose control of quality. Were not going to know what to do with the results.

Thats exactly what has happened, said Osterholm. The FDA needs to bring much more discipline to this area and they need to articulate it clearly, he said.

A key issue is the accuracy of the tests, which rely on measures known as sensitivity and specificity. A highly sensitive test will capture all true positive results. A highly specific test would identify all true negative results.

In April, researchers at the University of California-San Francisco, led by immunologist Dr. Alexander Marson, analyzed 14 COVID-19 serology tests on the market and found that all but one turned up false-positive results, indicating that someone had antibodies to the coronavirus when they actually did not. False-positive rates reached as high as 16% in the study, which has not yet been peer-reviewed.

Unreliable results worry Dr. Jeff Duchin, the public health officer for Seattle and King County, Washington, where the first surge of COVID cases emerged in the U.S. A person who tests positive for antibodies that dont exist may mistakenly believe he or she is free to ignore guidance about preventing infection, potentially spreading the disease. Regardless of whether you test positive or negative, the workplace still needs to take steps, he said. They shouldnt think a testing program in any way relieves them of that responsibility.

FDA officials said theyre working now with the National Cancer Institute to independently validate serology tests on the market. Until that list is public, users must rely on the relatively few that have received the emergency-use authorizations to date. More than 190 others have asked for that authorization, pending FDA review.

But consumers may have little control, because they are most likely getting tests from their employers or doctors, with little understanding of why those products were chosen.

There isnt a national standard, there isnt a one-stop shop or a Consumer Reports for antibody tests, Becker said. I dont expect a member of the public is going to be able to figure this out.

Even savvy physicians can have trouble. US Acute Care Solutions, a physician-owned medical services group, was trying out a Chinese-made test supplied by Minneapolis-based Premier Biotech, with plans to test its staff of more than 3,500 doctors and employees, said the groups chief medical officer, Dr. Amer Aldeen. That test has been widely used, including in recent controversial serology surveys conducted by Stanford University and the University of Southern California.

When USACS used it, the Premier test failed to detect antibodies in several employees who had been ill and tested positive for the coronavirus on diagnostic tests, Aldeen said. The results could have been caused by faulty instructions rather than flaws in the test itself, he said. Still, the Premier test has not received FDA authorization and the results gave him pause.

It does no good to select a test that isnt FDA-approved, he said.

In a statement, Premier Biotech officials said they anticipate exceeding FDA standards, which call for tests that are at least 90% accurate in identifying positive antibodies in a sample and 95% accurate in identifying samples that contain no antibody.

Some might ask why the FDA didnt just identify several reliable antibody tests and require their use to avoid the chaos. An FDA official said making that type of choice would be outside the scope of the agencys responsibilities.

FDAs lane is to review these tests and make sure that they are safe and accurate for the American people, said spokesperson Emma Spaulding. It wouldnt be within our lane to say which test must be used.

Although health officials understand the desire for a test that could provide comfort amid the uncertainty of COVID-19, Duchin advised employers and consumers to wait a little longer.

There are costs to testing with unvalidated tests that might outweigh the benefits of satisfying your curiosity, he said.

View original post here:
Hype collides with science as FDA tries to rein in "Wild West" of COVID blood tests - wausaupilotandreview.com

Recommendation and review posted by Bethany Smith

At some point in their lives most men will struggle with penile health issues, when it comes to this these issues involve more than erections, ejaculations, and reproduction as poor penile health can be a sign of an underlying health condition.

Additionally issues that affect the penis can also impact other areas of your life including emotionally and socially. Bottom line is that routine maintenance in this area can also help to ensure optimum performance which includes managing stress, getting enough sleep, being physically active, and following a healthy well balanced diet.According to research from Harvard University men should masturbate(routine maintenance) 21 times a month to reduce the odds of prostate cancer by 33%.

Simply masturbating 21+ times a month is not enough to guarantee to avoid prostate cancer, but added to a healthy diet full of organic produce, getting enough sleep, managing stress, being active and exercising, this will go a long way. Ian Kerner, PhD, recommends a plant based diet and incorporating plenty of fish rich in Omega-3 fatty acids, as well as consuming red foods such as tomatoes that are rich in lycopene, as well as soy products that contain isoflavones, along with getting regular physicals that include a prostate exam, and plenty of exercise.

Diet and nutrition play a bigger part in health than most people understand, and this includes penile health. Certain types of food have been shown to affect penis health, for example studies have shown that diets rich in flavonoids, which occur naturally in fruits, vegetables and whole grains, are associated with a reduced risk of erectile dysfunction in men under the age of 70.

There are many things that can affect an erection like poor health, smoking, and certain medications. Following a sub par diet, how much you eat, and how often you eat can affect your mood, energy levels, blood flow, and hormones which are all very important to your sex life.

It stands to reason that if certain foods can boost your erection, keep sperm healthy, and boost testosterone levels then eating habits exist that can also kill your libido. Unhealthy fats and added sugars can exacerbate erectile issues, and lower testosterone levels. Alcohol is a depressant which can numb the feeling of sexual stimulation, alter the blood flow in/out of the penis, and decrease testosterone levels sapping libido, energy, and moods.

Achieving and maintaining an erection requires good blood flow and plenty of nitric oxide. Flavonoids have been shown to improve cardiovascular health by helping to increase blood flow and the concentration of nitric oxide in the blood. Dark chocolate is rich in flavonoids, other choices include tea, citrus fruits, berries, apples, legumes, onions, tomatoes, broccoli, tea, grapes, celery, red peppers, ginger, red cabbage, asparagus, and leafy greens.

Pistachios are good for more than a snack, a study published in the International Journal of Impotence Research suggests that consuming these nuts for several weeks improved several parameters of ED including improved International Index of Erectile function scores, improved cholesterol levels and improved blood pressure with no notable side effects being observed.

Watermelon may help to improve sexual function as a study from Texas A&M University found connections between ED and watermelon, suggesting that citrulline found in watermelon helped to relax blood vessels and improved blood flow in a similar manner as to medications for ED.

Bananas are a great source of potassium which is great for keeping the heart and circulation strong. Potassium also keeps blood pressure in check by stabilizing sodium levels. Bananas are also a rich source of vitamin B which helps to increase energy levels, and combat stress that can lead to erectile dysfunction.

Salmon is a great source of omega-3 fatty acids which can help to enhance blood flow and enhance erectile function by helping to relax your arteries easing the way for blood to flow to the entire body without exception, including your penis. Salmon also contains vitamin D, selenium and magnesium which are all required to support testosterone levels and healthy sperm.

Anthocyanins are great for cardiovascular health, cherries are loaded with anthocyanins, which are flavonoids, that help to protect your artery walls and help prevent fatty plaques from forming in the arteries ensuring good blood flow and circulation.

Soluble fiber such as that in oatmeal has been shown to be great for satiety, fighting inflammation, to lower cholesterol levels and helps to keep your blood vessels smooth, healthy and stretchy, which also can apply to penis health.

Cruciferous vegetables such as broccoli can help to combat cancer, and the high vitamin C content helps to boost blood circulation and it has been linked to an improved libido. Cruciferous veggies such as bok choy, cabbage, and Brussels sprouts also contain glucobrassicins which help to clear the body of excess oestrogen which may help to boost your sex drive.

The antioxidant phytochemical resveratrol helps to open arteries by enhancing the production of nitric oxide, production of nitric oxide allows blood vessels to expand, and increases blood flow. Resveratrol works by expanding the tiny and main arteries in the penis much like medications for ED. It also helps to block enzymes that trigger the body to push away testosterone, which will help maintain high levels of the hormone and strong erections that should last well beyond foreplay.

After reaching the age of 30 testosterone levels begin to decrease, fortunately there are simple diet fixes that may help you, and because your brain, heart and penis are all intimately connected this is also good for your overall health and well being. Aging also affects your penis, as a result many men experience erectile difficulties, if you are one of them please consult with your physician as it can be an indication of an underlying condition that shouldnt be ignored. Your physician can work with you to help determine the cause and work towards a solution, often lifestyle changes can help.

Read the original post:
Reducing The Risk Of Erectile Dysfunction With Nutrition - Anti Aging News

Recommendation and review posted by Bethany Smith

Pedigree, a record of ancestry or purity of breed. Studbooks (listings of pedigrees for horses, dogs, etc.) and herdbooks (records for cattle, swine, sheep, etc.) are maintained by governmental or private record associations or breed organizations in many countries.

Read More on This Topic

consanguinity: Inbreeding and pedigree construction

Measurement of inbreeding in terms of the degree of consanguinity between two parents is another significant application of data on consanguinity....

In human genetics, pedigree diagrams are utilized to trace the inheritance of a specific trait, abnormality, or disease. A male is represented by a square or the symbol , a female by a circle or the symbol . Mating is shown by a horizontal line (marriage line) connecting a male symbol and a female symbol; offspring symbols are connected in a row (sibship line) beneath the mated pair. The offspring symbols appear from left to right in the order of birth and are connected to the marriage line by a vertical line. Possession of the character under study is shown by a solid or blackened symbol, and absence is shown by an open or clear symbol. Multiple births are designated by joining the individual symbols to the same point on the sibship line. Siblings not shown as individual symbols are indicated by a number within a large symbol for each sex.

Read the original here:
pedigree | Definition, Breeding, & Symbols | Britannica

Recommendation and review posted by Bethany Smith

American scientist and cytogeneticist

Barbara McClintock (June 16, 1902 September 2, 1992) was an American scientist and cytogeneticist who was awarded the 1983 Nobel Prize in Physiology or Medicine. McClintock received her PhD in botany from Cornell University in 1927. There she started her career as the leader in the development of maize cytogenetics, the focus of her research for the rest of her life. From the late 1920s, McClintock studied chromosomes and how they change during reproduction in maize. She developed the technique for visualizing maize chromosomes and used microscopic analysis to demonstrate many fundamental genetic ideas. One of those ideas was the notion of genetic recombination by crossing-over during meiosisa mechanism by which chromosomes exchange information. She produced the first genetic map for maize, linking regions of the chromosome to physical traits. She demonstrated the role of the telomere and centromere, regions of the chromosome that are important in the conservation of genetic information. She was recognized as among the best in the field, awarded prestigious fellowships, and elected a member of the National Academy of Sciences in 1944.

During the 1940s and 1950s, McClintock discovered transposition and used it to demonstrate that genes are responsible for turning physical characteristics on and off. She developed theories to explain the suppression and expression of genetic information from one generation of maize plants to the next. Due to skepticism of her research and its implications, she stopped publishing her data in 1953.

Later, she made an extensive study of the cytogenetics and ethnobotany of maize races from South America. McClintock's research became well understood in the 1960s and 1970s, as other scientists confirmed the mechanisms of genetic change and protein expression that she had demonstrated in her maize research in the 1940s and 1950s. Awards and recognition for her contributions to the field followed, including the Nobel Prize in Physiology or Medicine, awarded to her in 1983 for the discovery of genetic transposition; she was the only woman to receive an unshared Nobel Prize in that category.

Barbara McClintock was born Eleanor McClintock on June 16, 1902 in Hartford, Connecticut, the third of four children born to homeopathic physician Thomas Henry McClintock and Sara Handy McClintock.[5] Thomas McClintock was the child of British immigrants; Sara Ryder Handy was descended from an old American Mayflower family. Marjorie, the oldest child, was born in October 1898; Mignon, the second daughter, was born in November 1900. The youngest, Malcolm Rider (called Tom), was born 18 months after Barbara. When she was a young girl, her parents determined that Eleanor, a "feminine" and "delicate" name, was not appropriate for her, and chose Barbara instead. McClintock was an independent child beginning at a very young age, a trait she later identified as her "capacity to be alone". From the age of three until she began school, McClintock lived with an aunt and uncle in Brooklyn, New York in order to reduce the financial burden on her parents while her father established his medical practice. She was described as a solitary and independent child. She was close to her father, but had a difficult relationship with her mother, tension that began when she was young.

The McClintock family moved to Brooklyn in 1908 and McClintock completed her secondary education there at Erasmus Hall High School; she graduated early in 1919. She discovered her love of science and reaffirmed her solitary personality during high school. She wanted to continue her studies at Cornell University's College of Agriculture. Her mother resisted sending McClintock to college, for fear that she would be unmarriageable, something that was common at the time. McClintock was almost prevented from starting college, but her father allowed her to just before registration began, and she matriculated at Cornell in 1919.

McClintock began her studies at Cornell's College of Agriculture in 1919. There, she participated in student government and was invited to join a sorority, though she soon realized that she preferred not to join formal organizations. Instead, McClintock took up music, specifically jazz. She studied botany, receiving a B.Sc in 1923. Her interest in genetics began when she took her first course in that field in 1921. The course was based on a similar one offered at Harvard University, and was taught by C. B. Hutchison, a plant breeder and geneticist. Hutchison was impressed by McClintock's interest, and telephoned to invite her to participate in the graduate genetics course at Cornell in 1922. McClintock pointed to Hutchison's invitation as a catalyst for her interest in genetics: "Obviously, this telephone call cast the die for my future. I remained with genetics thereafter." Although it has been reported that women could not major in genetics at Cornell, and therefore her MS and PhDearned in 1925 and 1927, respectivelywere officially awarded in botany, recent research has revealed that women were permitted to earn graduate degrees in Cornell's Plant Breeding Department during the time that McClintock was a student at Cornell.

During her graduate studies and postgraduate appointment as a botany instructor, McClintock was instrumental in assembling a group that studied the new field of cytogenetics in maize. This group brought together plant breeders and cytologists, and included Marcus Rhoades, future Nobel laureate George Beadle, and Harriet Creighton. Rollins A. Emerson, head of the Plant Breeding Department, supported these efforts, although he was not a cytologist himself.

She also worked as a research assistant for Lowell Fitz Randolph and then for Lester W. Sharp, both Cornell botanists.[20]

McClintock's cytogenetic research focused on developing ways to visualize and characterize maize chromosomes. This particular part of her work influenced a generation of students, as it was included in most textbooks. She also developed a technique using carmine staining to visualize maize chromosomes, and showed for the first time the morphology of the 10 maize chromosomes. This discovery was made because she observed cells from the microspore as opposed to the root tip. By studying the morphology of the chromosomes, McClintock was able to link specific chromosome groups of traits that were inherited together. Marcus Rhoades noted that McClintock's 1929 Genetics paper on the characterization of triploid maize chromosomes triggered scientific interest in maize cytogenetics, and attributed to her 10 of the 17 significant advances in the field that were made by Cornell scientists between 1929 and 1935.

In 1930, McClintock was the first person to describe the cross-shaped interaction of homologous chromosomes during meiosis. The following year, McClintock and Creighton proved the link between chromosomal crossover during meiosis and the recombination of genetic traits. They observed how the recombination of chromosomes seen under a microscope correlated with new traits. Until this point, it had only been hypothesized that genetic recombination could occur during meiosis, although it had not been shown genetically. McClintock published the first genetic map for maize in 1931, showing the order of three genes on maize chromosome 9. This information provided necessary data for the crossing-over study she published with Creighton; they also showed that crossing-over occurs in sister chromatids as well as homologous chromosomes. In 1938, she produced a cytogenetic analysis of the centromere, describing the organization and function of the centromere, as well as the fact that it can divide.

McClintock's breakthrough publications, and support from her colleagues, led to her being awarded several postdoctoral fellowships from the National Research Council. This funding allowed her to continue to study genetics at Cornell, the University of Missouri, and the California Institute of Technology, where she worked with E. G. Anderson. During the summers of 1931 and 1932, she worked at the University of Missouri with geneticist Lewis Stadler, who introduced her to the use of X-rays as a mutagen. Exposure to X-rays can increase the rate of mutation above the natural background level, making it a powerful research tool for genetics. Through her work with X-ray-mutagenized maize, she identified ring chromosomes, which form when the ends of a single chromosome fuse together after radiation damage. From this evidence, McClintock hypothesized that there must be a structure on the chromosome tip that would normally ensure stability. She showed that the loss of ring-chromosomes at meiosis caused variegation in maize foliage in generations subsequent to irradiation resulting from chromosomal deletion. During this period, she demonstrated the presence of the nucleolus organizer region on a region on maize chromosome 6, which is required for the assembly of the nucleolus. In 1933, she established that cells can be damaged when nonhomologous recombination occurs. During this same period, McClintock hypothesized that the tips of chromosomes are protected by telomeres.

McClintock received a fellowship from the Guggenheim Foundation that made possible six months of training in Germany during 1933 and 1934. She had planned to work with Curt Stern, who had demonstrated crossing-over in Drosophila just weeks after McClintock and Creighton had done so; however, Stern emigrated to the United States. Instead, she worked with geneticist Richard B. Goldschmidt, who was a director of the Kaiser Wilhelm Institute for Biology in Berlin.[32] She left Germany early amidst mounting political tension in Europe, and returned to Cornell, remaining there until 1936, when she accepted an Assistant Professorship offered to her by Lewis Stadler in the Department of Botany at the University of Missouri-Columbia. While still at Cornell, she was supported by a two-year Rockefeller Foundation grant obtained for her through Emerson's efforts.

During her time at Missouri, McClintock expanded her research on the effect of X-rays on maize cytogenetics. McClintock observed the breakage and fusion of chromosomes in irradiated maize cells. She was also able to show that, in some plants, spontaneous chromosome breakage occurred in the cells of the endosperm. Over the course of mitosis, she observed that the ends of broken chromatids were rejoined after the chromosome replication. In the anaphase of mitosis, the broken chromosomes formed a chromatid bridge, which was broken when the chromatids moved towards the cell poles. The broken ends were rejoined in the interphase of the next mitosis, and the cycle was repeated, causing massive mutation, which she could detect as variegation in the endosperm. This breakagerejoiningbridge cycle was a key cytogenetic discovery for several reasons. First, it showed that the rejoining of chromosomes was not a random event, and second, it demonstrated a source of large-scale mutation. For this reason, it remains an area of interest in cancer research today.

Although her research was progressing at Missouri, McClintock was not satisfied with her position at the University. She recalled being excluded from faculty meetings, and was not made aware of positions available at other institutions. In 1940, she wrote to Charles Burnham, "I have decided that I must look for another job. As far as I can make out, there is nothing more for me here. I am an assistant professor at $3,000 and I feel sure that that is the limit for me." Initially, McClintock's position was created especially for her by Stadler, and might have depended on his presence at the university. McClintock believed she would not gain tenure at Missouri, even though according to some accounts, she knew she would be offered a promotion from Missouri in the spring of 1942. Recent evidence reveals that McClintock more likely decided to leave Missouri because she had lost trust in her employer and in the University administration, after discovering that her job would be in jeopardy if Stadler were to leave for Caltech, as he had considered doing. The university's retaliation against Stadler amplified her sentiments.

In early 1941, she took a leave of absence from Missouri in hopes of finding a position elsewhere. She accepted a visiting Professorship at Columbia University, where her former Cornell colleague Marcus Rhoades was a professor. Rhoades also offered to share his research field at Cold Spring Harbor on Long Island. In December 1941, she was offered a research position by Milislav Demerec, the newly appointed acting director of the Carnegie Institution of Washington's Department of Genetics Cold Spring Harbor Laboratory; McClintock accepted his invitation despite her qualms and became a permanent member of the faculty.

After her year-long temporary appointment, McClintock accepted a full-time research position at Cold Spring Harbor Laboratory. There, she was highly productive and continued her work with the breakage-fusion-bridge cycle, using it to substitute for X-rays as a tool for mapping new genes. In 1944, in recognition of her prominence in the field of genetics during this period, McClintock was elected to the National Academy of Sciencesonly the third woman to be elected. The following year she became the first female president of the Genetics Society of America; she had been elected its vice-president in 1939. In 1944 she undertook a cytogenetic analysis of Neurospora crassa at the suggestion of George Beadle, who used the fungus to demonstrate the one geneone enzyme relationship. He invited her to Stanford to undertake the study. She successfully described the number of chromosomes, or karyotype, of N. crassa and described the entire life cycle of the species. Beadle said, "Barbara, in two months at Stanford, did more to clean up the cytology of Neurospora than all other cytological geneticists had done in all previous time on all forms of mold." N. crassa has since become a model species for classical genetic analysis.

In the summer of 1944 at Cold Spring Harbor Laboratory, McClintock began systematic studies on the mechanisms of the mosaic color patterns of maize seed and the unstable inheritance of this mosaicism. She identified two new dominant and interacting genetic loci that she named Dissociation (Ds) and Activator (Ac). She found that the Dissociation did not just dissociate or cause the chromosome to break, it also had a variety of effects on neighboring genes when the Activator was also present, which included making certain stable mutations unstable. In early 1948, she made the surprising discovery that both Dissociation and Activator could transpose, or change position, on the chromosome.

She observed the effects of the transposition of Ac and Ds by the changing patterns of coloration in maize kernels over generations of controlled crosses, and described the relationship between the two loci through intricate microscopic analysis. She concluded that Ac controls the transposition of the Ds from chromosome9, and that the movement of Ds is accompanied by the breakage of the chromosome. When Ds moves, the aleurone-color gene is released from the suppressing effect of the Ds and transformed into the active form, which initiates the pigment synthesis in cells. The transposition of Ds in different cells is random, it may move in some but not others, which causes color mosaicism. The size of the colored spot on the seed is determined by stage of the seed development during dissociation. McClintock also found that the transposition of Ds is determined by the number of Ac copies in the cell.

Between 1948 and 1950, she developed a theory by which these mobile elements regulated the genes by inhibiting or modulating their action. She referred to Dissociation and Activator as "controlling units"later, as "controlling elements"to distinguish them from genes. She hypothesized that gene regulation could explain how complex multicellular organisms made of cells with identical genomes have cells of different function. McClintock's discovery challenged the concept of the genome as a static set of instructions passed between generations. In 1950, she reported her work on Ac/Ds and her ideas about gene regulation in a paper entitled "The origin and behavior of mutable loci in maize" published in the journal Proceedings of the National Academy of Sciences. In summer 1951, she reported her work on the origin and behavior of mutable loci in maize at the annual symposium at Cold Spring Harbor Laboratory, presenting a paper of the same name. The paper delved into the instability caused by Ds and Ac or just Ac in four genes, along with the tendency of those genes to unpredictably revert to the wild phenotype. She also identified "families" of transposons, which did not interact with one another.

Her work on controlling elements and gene regulation was conceptually difficult and was not immediately understood or accepted by her contemporaries; she described the reception of her research as "puzzlement, even hostility". Nevertheless, McClintock continued to develop her ideas on controlling elements. She published a paper in Genetics in 1953, where she presented all her statistical data, and undertook lecture tours to universities throughout the 1950s to speak about her work. She continued to investigate the problem and identified a new element that she called Suppressor-mutator (Spm), which, although similar to Ac/Ds, acts in a more complex manner. Like Ac/Ds, some versions could transpose on their own and some could not; unlike Ac/Ds, when present, it fully suppressed the expression of mutant genes when they normally would not be entirely suppressed. Based on the reactions of other scientists to her work, McClintock felt she risked alienating the scientific mainstream, and from 1953 was forced to stop publishing accounts of her research on controlling elements.

In 1957, McClintock received funding from the National Academy of Sciences to start research on indigenous strains of maize in Central America and South America. She was interested in studying the evolution of maize through chromosomal changes, and being in South America would allow her to work on a larger scale. McClintock explored the chromosomal, morphological, and evolutionary characteristics of various races of maize. After extensive work in the 1960s and 1970s, McClintock and her collaborators published the seminal study The Chromosomal Constitution of Races of Maize, leaving their mark on paleobotany, ethnobotany, and evolutionary biology.

McClintock officially retired from her position at the Carnegie Institution in 1967, and was made a Distinguished Service Member of the Carnegie Institution of Washington. This honor allowed her to continue working with graduate students and colleagues in the Cold Spring Harbor Laboratory as scientist emerita; she lived in the town. In reference to her decision 20 years earlier to stop publishing detailed accounts of her work on controlling elements, she wrote in 1973:

Over the years I have found that it is difficult if not impossible to bring to consciousness of another person the nature of his tacit assumptions when, by some special experiences, I have been made aware of them. This became painfully evident to me in my attempts during the 1950s to convince geneticists that the action of genes had to be and was controlled. It is now equally painful to recognize the fixity of assumptions that many persons hold on the nature of controlling elements in maize and the manners of their operation. One must await the right time for conceptual change.

The importance of McClintock's contributions was revealed in the 1960s, when the work of French geneticists Francois Jacob and Jacques Monod described the genetic regulation of the lac operon, a concept she had demonstrated with Ac/Ds in 1951. Following Jacob and Monod's 1961 Journal of Molecular Biology paper "Genetic regulatory mechanisms in the synthesis of proteins", McClintock wrote an article for American Naturalist comparing the lac operon and her work on controlling elements in maize. Even late in the twentieth century, McClintock's contribution to biology was still not widely acknowledged as amounting to the discovery of genetic regulation.

McClintock was widely credited with discovering transposition after other researchers finally discovered the process in bacteria, yeast, and bacteriophages in the late 1960s and early 1970s. During this period, molecular biology had developed significant new technology, and scientists were able to show the molecular basis for transposition. In the 1970s, Ac and Ds were cloned by other scientists and were shown to be class II transposons. Ac is a complete transposon that can produce a functional transposase, which is required for the element to move within the genome. Ds has a mutation in its transposase gene, which means that it cannot move without another source of transposase. Thus, as McClintock observed, Ds cannot move in the absence of Ac.[65] Spm has also been characterized as a transposon. Subsequent research has shown that transposons typically do not move unless the cell is placed under stress, such as by irradiation or the breakage-fusion-bridge cycle, and thus their activation during stress can serve as a source of genetic variation for evolution. McClintock understood the role of transposons in evolution and genome change well before other researchers grasped the concept. Nowadays, Ac/Ds is used as a tool in plant biology to generate mutant plants used for the characterization of gene function.

In 1947, McClintock received the Achievement Award from the American Association of University Women. She was elected a Fellow of the American Academy of Arts and Sciences in 1959.[68] In 1967, McClintock was awarded the Kimber Genetics Award; three years later, she was given the National Medal of Science by Richard Nixon in 1970. She was the first woman to be awarded the National Medal of Science.[71]Cold Spring Harbor named a building in her honor in 1973. She received the Louis and Bert Freedman Foundation Award and the Lewis S. Rosensteil Award in 1978. In 1981, she became the first recipient of the MacArthur Foundation Grant, and was awarded the Albert Lasker Award for Basic Medical Research, the Wolf Prize in Medicine and the Thomas Hunt Morgan Medal by the Genetics Society of America. In 1982, she was awarded the Louisa Gross Horwitz Prize from Columbia University for her research in the "evolution of genetic information and the control of its expression."

Most notably, she received the Nobel Prize for Physiology or Medicine in 1983, the first woman to win that prize unshared, and the first American woman to win any unshared Nobel Prize.[74] It was given to her by the Nobel Foundation for discovering "mobile genetic elements"; this was more than 30 years after she initially described the phenomenon of controlling elements. She was compared to Gregor Mendel in terms of her scientific career by the Swedish Academy of Sciences when she was awarded the Prize.

She was elected a Foreign Member of the Royal Society (ForMemRS) in 1989. McClintock received the Benjamin Franklin Medal for Distinguished Achievement in the Sciences of the American Philosophical Society in 1993. She was awarded 14 Honorary Doctor of Science degrees and an Honorary Doctor of Humane Letters. In 1986 she was inducted into the National Women's Hall of Fame. During her final years, McClintock led a more public life, especially after Evelyn Fox Keller's 1983 biography of her, A Feeling for the Organism, brought McClintock's story to the public. She remained a regular presence in the Cold Spring Harbor community, and gave talks on mobile genetic elements and the history of genetics research for the benefit of junior scientists. An anthology of her 43 publications The Discovery and Characterization of Transposable Elements: The Collected Papers of Barbara McClintock was published in 1987.

The McClintock Prize is named in her honour.[79] Laureates of the award include David Baulcombe, Detlef Weigel Robert A. Martienssen, Jeffrey D. Palmer and Susan R. Wessler.[79]

McClintock spent her later years, post Nobel Prize, as a key leader and researcher in the field at Cold Spring Harbor Laboratory on Long Island, New York. McClintock died of natural causes in Huntington, New York, on September 2, 1992 at the age of 90; she never married or had children.

In 2001, McClintock was the subject of a biography by the science historian Nathaniel C. Comfort's The Tangled Field: Barbara McClintock's Search for the Patterns of Genetic Control. Comfort's biography contests the claim that McClintock was marginalized by other scientists, which he calls the "McClintock Myth" and argues was perpetuated both by McClintock herself as well as in the earlier biography by Keller. Keller argued that because McClintock felt like an outsider within her field, (in part, because of her gender) she was able to look at her scientific subjects from a perspective different than the dominant one leading to several important insights.[80] Keller shows how this led many of her colleagues to reject her ideas and undermine her abilities for many years. For example, when McClintock presented her findings that the genetics of maize did not conform to Mendelian distributions, geneticist Sewall Wright expressed the belief that she did not understand the underlying mathematics of her work, a belief he had also expressed towards other women at the time. In addition, geneticist Lotte Auerbach recounted that Joshua Lederberg returned from a visit to McClintock's lab with the remark: 'By God, that woman is either crazy or a genius.' " As Auerbach recounts, McClintock had thrown Lederberg and his colleagues out after half an hour 'because of their arrogance. She was intolerant of arrogance... She felt she had crossed a desert alone and no one had followed her.'" Comfort, however, asserts that McClintock was not discriminated against because of her gender, citing that she was well regarded by her professional peers, even in the early years of her career.

Many recent biographical works on women in science feature accounts of McClintock's work and experience. She is held up as a role model for girls in such works of children's literature as Edith Hope Fine's Barbara McClintock, Nobel Prize Geneticist, Deborah Heiligman's Barbara McClintock: Alone in Her Field and Mary Kittredge's Barbara McClintock. A recent biography for young adults by Naomi Pasachoff, Barbara McClintock, Genius of Genetics, provides a new perspective, based on the current literature.

On May 4, 2005, the United States Postal Service issued the "American Scientists" commemorative postage stamp series, a set of four 37-cent self-adhesive stamps in several configurations. The scientists depicted were Barbara McClintock, John von Neumann, Josiah Willard Gibbs, and Richard Feynman. McClintock was also featured in a 1989 four-stamp issue from Sweden which illustrated the work of eight Nobel Prize-winning geneticists. A small building at Cornell University and a laboratory building at Cold Spring Harbor Laboratory were named for her. A street has been named after her in the new "Adlershof Development Society" science park in Berlin.

Some of McClintock's personality and scientific achievements were referred to in Jeffrey Eugenides's 2011 novel The Marriage Plot, which tells the story of a yeast geneticist named Leonard who suffers from bipolar disorder. He works at a laboratory loosely based on Cold Spring Harbor. The character reminiscent of McClintock is a reclusive geneticist at the fictional laboratory, who makes the same discoveries as her factual counterpart.

Judith Pratt wrote a play about McClintock, called MAIZE, which was read at Artemesia Theatre in Chicago in 2015, and was produced in Ithaca NY, the home of Cornell University, in FebruaryMarch 2018.[88]

Read the original:
Barbara McClintock - Wikipedia

Recommendation and review posted by Bethany Smith

Few people have the ability, dedication or patience to train a dog to trial standard let alone to sell at public auction, so imagine the elation when Emma Gray sold her first bitch for a record breaking 14,000gns with her second at a world beating, 18,000gns.

But then the Northumberland shepherdess from Fallowlees, Morpeth, is no ordinary dog handler. As the first woman to win the Northumberland Nursery League in 2014 and the English Nursery championship in 2016, Emma has also competed on the world stage both in The Netherlands and in Scotland when the event was staged at Fearn Farm, Tain.

And next month, the young mother who was once dubbed the UKs loneliest shepherd, her husband, Ewan Irvine and son, Len, will be starring in the latest series of This Farming Life.

No stranger to the TV screen, Emma has previously shown her dog handling talents when Countryfile and Robson Green visited Fallowlees. She has also travelled down to London to be on the Alan Titchmarsh show.

Out with this new found screen fame, it is nevertheless Emmas dogs that come first after Ewan and Len of course!

When you live on a farm, youre told from an early age that everything has to earn its keep, so naturally, when I said I wanted a dog, it had to get a Collie, said Emma, who was brought up on her parents Richard and Helen Gray Muirfield farm just outside Hawick.

That was at the tender age of 13. Bitten by the dog training bug, she attended the only shepherding and dog handling course in the UK, four years later at Kirkleyhall College in Northumberland.

It is unbelievable what you can train dogs to do and while every dog is different, you do need to have sheep to train them which is why I went into sheep farming, added Emma who at her first competitive trial, at 21 years of age, came second with the home-bred unregistered bitch, Fly at the Hawick Farm Nursery event.

After college, she did contract shepherding to include three lambings a year, to prove herself and two years later in 2011, took on the lease of the National Trusts remote and extremely exposed, 100-acre Fallowlees upland unit, just outside Morpeth in Northumberland.

She left home, with just four dogs and a suitcase to move into her new abode which in those days was completely bereft of any power or phone reception.

Some 200 draft Blackface ewes were bought at Lanark for crossing to Bluefaced Leicester tups to breed home-bred Scotch Mules which are now put to Texel and Aberfield rams.

Since then, Emma has also taken on a share farming contract on the neighbouring unit at Healy Mill Farm and now farms 400 Texel cross Scotch Mules across both farms, with the flock tupped to Texel and Aberfield rams. Emma and Ewan have also invested in 25 Bluegrey and Whitebred Shorthorn cows.

It is nevertheless the dogs that take priority but then that is no surprise when you see what can be achieved training pups into top class trial dogs. Emmas first big victory as the first female to win the Northumberland Nursery league, in 2014 came with Roy, a dog purchased as a four-month-old puppy from Paul Bristow.

I saw him as a pup and just liked what he did at that age. He was really bold and had a lot of power and turned out a really good work dog. He qualified for the team at the English National as well as for the world sheepdog trials in Tain.

Two years later in 2016, Tweeddale Jamie a dog bought as an eight-week-old pup from Scottish breeder, Dean Aitken, also won the English Nursery final and went on to qualify for the English National where he finished reserve overall at 18months of age. He too qualified for the world trials which were staged in The Netherlands that year and came in third on his qualifying field.

Notably, his son, Telf Joff, scored a hat-trick for Emma, when he too won the Northumberland Nursery League and the English Nursery final when his co-pilot was eight months pregnant at the time!

That was in 2019, a year which not only saw Emma give birth to baby Len, but also produce a new record price for a Border Collie bitch sold at public auction when Brenna, which always stood second to Joff at trials, sold for 14,000gns at Craven Auction Marts Skipton sheepdog sale to America.

A daughter of Aled Owens Welsh National and International supreme champion, Llangwm Cap, Brenna was knocked down to Dr Pamela Helton who farms 60 Swedish Gotland sheep in Maryland, and also runs dogs in eastern and mid-western US trials.

If that wasnt enough to be going on with, the family returned to Skipton earlier this year to sell Megan for the world record price of 18,000gns, again to the US. Another backed by the best of genetics, Megan is by the twice International champion, Roy from Welsh breeder, Ross Games and out of Co Durham-based Lynne Morelands Maggie which is a little sister to Ricky Hutchinsons International supreme winner, Jock.

Megan was bought as an eight-month-old pup from Lynne Moreland and sold over the phone to Wagyu cattle farmer and businessman, Brian Stamps, Tuttle, Grady County, central Oklahoma.

Social media has been really good for advertising working Border Collie dogs on line, and it has been great to see them sell for their true value at auction when you think a Cockapoo pup will sell at 3000 as an eight-week-old pup compared to 300 for a Collie at the same age, said Emma.

As a result, Emma and Ewan, a fireman to trade who is now equally enthusiastic about dog training and trialling, have sold dogs as far afield as the Faroe Islands, Canada, America, Germany, France, Sweden and even as far as North Korea.

But in contrast to many who tend to concentrate on breeding the best, Emma prefers to buy pups from the best bloodlines, although she does also breed them.

I always like to buy dogs as pups and train them up. I like them to have a good free-range puppyhood when they learn something new every day. Pups learn nothing in a kennel.

It doesnt matter where you get a puppy from but it has good to have a good puppyhood and if you buy a well bred one, youll increase your chances of getting a good working dog, said Emma.

Once they get to that nuisance stage at about eight to nine months of age and are looking to kep or chase sheep, they are put in kennels and brought out two or three times a day for schooling and to get them onto their sides. Initially, they get to run round and round a big pen of sheep in the middle of a field and once they have mastered that, the pen is removed and they are encouraged to kep and bring the sheep to Emma.

Dont correct them too much when theyre young, and dont sicken them. Ten minutes two twice a day and then work it up to 20-30minutes when theyre working well. Its arithmetic on a treadmill for them

The best working dogs have plenty power and a good heart with the majority bred from leading trial dogs. Most dogs can be good farm dogs, but a sheepdog trial is the true test of a dog. Working four sheep round a course is a lot more difficult than working a flock of sheep, she said.

Not all dogs get to trial standard either, and while all good handlers have pot lickers, Emma maintains there is always a dog for the right person as not everyone wants a trial dog. With 20 plus dogs on the go at any one time, she always has something to suit people looking to buy a dog privately too.

All dogs are capable of learning but they do have a short life, so you are better to get them working to full potential at two years of age than at four. We like to have ours broken by 18months of age and then get them doing trial work working on farm as much as possible after that, concluded Emma.

ON THE spot

Best investment? : 'My big red Honda bike, most reliable machine ever!!'

Best advice?: 'So many 'Buy the best you can afford; Dont let a shepherdess drive a tractor and Dont work harder, think smarter.'

Biggest achievement?: 'Securing the tenancy of Fallowlees that's how it all started.'

Best working dog you have seen?: 'Ricky Hutchinsons Sweep.'

What you miss most in 2020 as a result of the pandemic?: 'The Royal Highland Show.'

Where do you want to be in 2030?: 'A ring fenced farm where the nearest supermarket isnt an hour away!'

Originally posted here:
Emma - the record breaking shepherdess - The Scottish Farmer

Recommendation and review posted by Bethany Smith

More News07 Jun 2020 | 11:28 PM

Bengaluru, June 7 (UNI) Mr. C Satyanandan, former Chief Engineer (South Zone) Doordarshan, has been elected as Chairman (2020-22) of the Bengaluru Centre of Institution of Electronics & Telecommunications Engineers (IETE), the leading professional body of Electronics, Telecommunications and Information Technology Engineers in the country.

Hyderabad, Jun 7 (UNI) Shriram Bioseed Genetics, a unit of DCM Shriram Ltd one of Indias leading conglomerates, on Sunday announced the launch of a new generation long shelf life and high yielding variety HYBRID TOMATO BIOSEED FLEXI HARVEST 4 here.

Visakhapatnam, Jun 7 (UNI) A 55-year-old man, who is working as an attender in Mandal Revenue Officer (MRO), died after consuming alcohol-based sanitizer believing that it was drinking water at Nakkapalle area in the district on Saturday night.

Hyderabad, Jun 7 (UNI) Telangana Health Minister Etala Rajender has said that the COVID-19 cases were increased in the state due to relaxation of lockdown.

Kakinada, Jun 7(UNI) District Food safety officer Kalyan Chakravarti has said that the food processing units managements should follow the food safety standards as it is mandatory on their part.

Read the original:
nCoV: 38 more test positive in Belagavi - United News of India

Recommendation and review posted by Bethany Smith

If a child is displaying unusual or rare symptoms and a doctor suspects that they may be genetic in origin, it can begin a cycle of testing that research has indicated could last aslong as 77 monthsor even longer. This is obviously a painstaking process, but doctors are under tremendous pressure to get the diagnosis right. A lot of time is spent analyzing testing options using the available knowledge of symptoms and previous literature in order to pinpoint the exact genetic test to order.

We must remember that there are about 20,000 genes in the human genome. Of which some 5,000 are recognized to be associated with at least one disease, if not more, and each disease can be associated with dozens of clinical symptoms. Imagine solving a puzzle with 5,000 to 20,000 pieces. But it is even more complicated than that. It becomes a puzzle within the puzzle. The way the genome is set up is that each gene is broken up into different pieces in and of itself. On top of that, there may be important variants within any of those pieces. Genetic testing has traditionally been a lot like fishing in a huge lake.

Historically, genetic testing has been disjointed with so much trial and error. The problem comes with continued negative results. It forces ordering of additional testing in order to identify variants that could be the genesis of the problem. Imagine if an accomplished fisherman was charged every single time he or she threw a lure into a lake. The costs would quickly add up.

Genetic testing becomes a repetitive cycle that causes families emotional and financial stress. The averagenumber of genetic testsa person with a rare disease goes through is four, with some patients having to undergo more than 10. These tests are extremely expensive and some can be quite invasive. Studies have shown theaverage cost of diagnosisreaching $21,099. All of this is referred to as a diagnostic odyssey, where an unfortunate result is delays in diagnoses that can effectively close the treatment window in cases where early treatment improves the prognosis.

Tests developed 10 to 15 years ago are still being run today by laboratories. However, genomic technologies have become more available and accessible recently and it is now possible to look at everything at once using whole genome testing. This new approach to genetic testing is not so much like fishing in a huge lake anymore. This new approach provides the most useful diagnostic data with a single test that is easier on patients and families and provides the shortest time to a diagnosis and the best chance at implementing treatments and eliminating the diagnostic odyssey.

Morestudiesare showing the clinical utility of sequencing the whole genome as acost-effective solution, saving as much as seven times the average cost of standard care. Clinicians ordering a single whole genome sequencing test right off the batprovide patients a better chance of not having to endure the long, cumbersome, and costly process ofmultiple single-gene tests. With whole genome sequencing , a patient needs only one sample and one turnaround time for the greatest chance to arrive at the correct diagnosis.

Just as important, with whole genome sequencing, negative test results do not require once again starting from scratch. If a new gene associated with the patient's suspected disease is reported the next day, and that patient had a variant in that gene, a clinician can make the connection through data reanalysis rather than by bringing the patient back in for a new sample.

Specifically, advances in whole genome sequencing bypass the mechanical step of isolating genes first. Analysis of the large amounts of data generated is made possible by the use of sophisticated algorithms applied via software that identifies variants that labs do not typically see when one starts by isolating genes. Variants can then be ranked by looking at genes that most closely match the patient's clinical symptoms or known inheritance patterns. For the first time, a broad set of variants can be looked at through two lenses: one that shows the severity of the identified changes, and the other that matches the changes with the clinical symptoms of the patient.

These are the ways whole genome testing is revolutionizing the entire genetic testing industry by providing a comprehensive analysis with the shortest time to diagnosis and thus saving patients a lot of money and the emotional toll that comes with a long wait for a diagnosis.

Christine Stanley, PhD, is the Chief Director of Clinical Genomics for Variantyx

Read more from the original source:
Better Genetic Testing Means Less Expensive And Emotionally Taxing Diagnosis - International Business Times

Recommendation and review posted by Bethany Smith

Cooper died on June 27, 2019. He had six months of bubble baths, music and nuzzling into his parents chests.

We ask ourselves: Why our child? Why is any child born with genetic conditions to parents who had no idea they even existed?', Mrs Tierney said.

Cooper Tierney died at 6 months old from mitochondrial disease caused by a genetic mutation on the gene REDFOX1.

This could happen to anybody. We never want to go through that again.

Earlier this year the Tierneys were among the first couples in Australia to undergo free genetic testing for more than 1300 genes linked to over 750 rare diseases parents can potentially pass on to their children.

Tuesday marks the official launch of the $20 million Mackenzies Mission trial.

Loading

The landmark preconception carrier testing trial is unprecedented, screening 10,000 couples for conditions including, spinal muscular atrophy (SMA), cystic fibrosis, fragile X syndrome and Coopers mitochondrial complex 1 deficiency.

The trial is designed to pave the way for carrier testing for any couple who wants it, co-lead investigator Edwin Kirk said.

I am very hopeful and hugely optimistic that we will be able to make a huge difference for Australian couples, Dr Kirk said.

We are talking about potentially hundreds of children a year who are born with severe, sometimes lethal, conditions whose parents only find out they had an increased chance of that condition after the child is born.

Health Minister Greg Hunt has said he wants a national screening program within 10 years.

Jonathan and Rachael Casella hold their baby daughter Mackenzie who was diagnosed with SMA and died at seven months.

The federal government-funded trial is named after Rachael and Jonathan Casellas daughter, Mackenzie, who was diagnosed with the most severe form of SMA and died at seven months in October 2017.

Mackenzies story has driven all of us working on the project, Dr Kirk said.

This information enables couples who learn they share the same genetic mutation to make informed decisions about family planning and full reproductive choice. They are also spared a 'diagnosis odyssey'- the painful and protracted search for the cause of their childs mysterious illness in the hope of finding a treatment.

Loading

Geneticists estimate everyone carries between three and five recessive genes for serious conditions. When both parents carry the same mutation, their child has a one in four chance of developing the corresponding genetic condition, and a one in two chance their child will be a carrier.

Would-be parents will be told they have a genetic mutation only if both individuals carry the same mutation for one of the conditions, roughly 1 per cent of the couples tested.

The trial is being coordinated by the Australian Genomics research network with laboratories in NSW, the ACT, Victoria and Western Australia.

Couples are recruited by participating GPs and other healthcare practitioners.

Investigators planned to eventually recruit pregnant women in their first trimester once they can be sure the COVID-19 pandemic will not delay test results.

The Tierneys jumped at the opportunity to participate in the pilot phase of the trial.

We are extremely thankful we were able to be part of this, Mrs Tierney said. It is very daunting looking into the unknown, but getting tested was the best thing we could have done for ourselves, for our children and for all the generations that come afterwards."

Cooper Tierney's parents hope his story will help inform other couples about the potential risk of genetic mutations.

Kate Aubusson is Health Editor of The Sydney Morning Herald.

Read the rest here:
'Why our child?': 10,000 couples to be tested for genetic mutations - Sydney Morning Herald

Recommendation and review posted by Bethany Smith

Final Report will add the analysis of the impact of COVID-19 on this industry.

Market Insight Reportshas released a new report on theDirect-to-consumer Genetic TestingMarket. This report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analysing the present scenario and future projections based on optimistic and likely scenarios. The report gives the detailed statistics about the market industries and their framework. The data which has been studied for preparing the report considers the existing key players as well as upcoming key players of the market.

Get a Sample Copy of the Report:

https://www.marketinsightsreports.com/reports/05132015841/global-direct-to-consumer-genetic-testing-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread/inquiry?source=coleofduty&Mode=88

Top Companies operating in the Global Direct-to-consumer Genetic Testing market profiled in the report : Quest Diagnostics, Laboratory Corporation of America, Myriad Genetics, African Ancestry, Gene by Gene, WeGene, MapMyGenome, Thermo Fisher, Color Genomics, Pathway Genomics, 23andMe, Helix

In addition, the Direct-to-consumer Genetic Testing Market report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market also the SWOT analysis that concludes the strengths, weaknesses, opportunities and threats impacting the segment of the overall market.

Global Direct-to-consumer Genetic Testing Market Split by Product Type and Applications:

Market Segment by Type, covers:

Disease Risk and HealthAncestry or GenealogyKinshipLifestyleMarket Segment by Applications, covers:

On-line SalesDoctors OfficeRegional Analysis For Direct-to-consumer Genetic Testing Market:

North America (United States, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, Colombia etc.)Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Browse Full Report :

https://www.marketinsightsreports.com/reports/05132015841/global-direct-to-consumer-genetic-testing-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread?source=coleofduty&Mode=88

Influence of the Direct-to-consumer Genetic Testing Market Report:

-Comprehensive assessment of all opportunities and risk in the Direct-to-consumer Genetic Testing market.

-Direct-to-consumer Genetic Testing market recent innovations and major events.

-Detailed study of business strategies for growth of the Direct-to-consumer Genetic Testing market-leading players.

-Conclusive study about the growth plot of Direct-to-consumer Genetic Testing market for forthcoming years.

-In-depth understanding of Direct-to-consumer Genetic Testing market-particular drivers, constraints and major micro markets.

-Favourable impression inside vital technological and market latest trends striking the Direct-to-consumer Genetic Testing market.

What are the market factors described in the report?

-Key Strategic Developments:This research includes R & D, new product launches, M & A, contracts, collaborations, partnerships, joint ventures, and global and regional scale.

-Key market features:Report, revenue, price, capacity, capacity utilization,total volume, production volume, production volume, consumption volume, import / export, supply / demand, cost, market share, CAGR, gross profit, etc. Evaluated the key market characteristics.In addition, this study provides a comprehensive survey of key market dynamics and their latest trends, along with relevant market segments and subsegments.

-Analytical Tools: TheGlobal Direct-to-consumer Genetic Testing Market Report contains accurately surveyed and evaluated data of the key industry players and their range in the market using several analytical tools.We analysed the growth of key players operating in the market using analytical tools such as Porters Five Forces Analysis, SWOT Analysis, Feasibility Studies, and Return on Investment Analysis

Note-All the reports that we list have been tracking the impact of COVID-19 the market. Both upstream and downstream of the entire supplychain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

ABOUT US:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

[emailprotected] | [emailprotected]

Link:
Direct-to-consumer Genetic Testing Market In-deep Analysis and Clinical Aspect Review 2020-2026 - Cole of Duty

Recommendation and review posted by Bethany Smith